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Nanotechnology appears to bring novel therapeutic devices using available drugs in the 
market to efficiently treat Neglected Diseases with less toxicity, high efficacy and improved 
bioavailability of drugs with extended release. 
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Highlights  
 
 Neglected Tropical Diseases affect large populations with little visibility and low 
political voice. 
 Few new drugs are in pipeline to treat 17 reported Neglected Tropical Diseases 
 Nanocarriers are promising devices for the treatment of Neglected Tropical Diseases 
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Abstract 
The study of neglected diseases has not received much attention, especially from public and private 
institutions over the last years, in terms of strong support for developing treatment for these diseases. 
Support in the form of substantial amounts of private and public investment is greatly needed in this 
area. Due to the lack of novel drugs for these diseases, nanobiotechnology has appeared as an 
important new breakthrough for the treatment of neglected diseases. Recently, very few reviews 
focusing on filiarasis, leishmaniasis, leprosy, malaria, onchocerciasis, schistosomiasis, 
trypanosomiasis, and tuberculosis, and dengue virus have been published. New developments in 
nanocarriers have made promising advances in the treatment of several kinds of diseases with less 
toxicity, high efficacy and improved bioavailability of drugs with extended release and fewer 
applications. This review deals with the current status of nanobiotechnology in the treatment of 
neglected diseases and highlights how it provides key tools for exploring new perspectives in the 
treatment of a wide range of diseases.  
 
1. Introduction 
1.1. General aspects of neglected diseases 
The WHO Special Programme for Research and Training in Tropical Diseases (WHO-TDR) 
defines a disease of poverty (DoP) as a disease that affects mainly the poor in developing countries, 
and it is divided into two classes (WHO, 2010a). The first class includes the “big three” DoPs: 
malaria, HIV/AIDS, and tuberculosis. These diseases have received considerable attention from the 
community and investment to eradicate them. Around 70% of drug development focuses on these 
diseases (Ponder, 2012). The other one comprises neglected tropical diseases (NTD). There are 
seventeen NTD, and these diseases affect populations with little visibility and low political voice. 
They cause discrimination and stigma and have a strong impact on morbidity and mortality; these 
diseases are practically neglected by the research community but can be prevented, controlled, and 
probably eliminated using adequate solutions (WHO, 2010b).  
In addition to the “big three” and NTD, BIO Ventures for Global Health, a nonprofit organization that 
specializes in accelerating research on medicines for developing countries, classifies diseases such as 
diarrheal diseases, cholera, and typhoid fever as DoP (Ponder, 2012). Policy Cures, another health 
nonprofit organization, lists 31 neglected diseases. This nonprofit organization considers an illness a 
disease of poverty if it meets three conditions: the disease strongly affects people in low-income 
countries; there is a need for different and new products; and the allocation of goods and services is 
not efficient (Moran et al., 2010). Table 1 lists the DoP identified by WHO, Policy Cures, and 
BioVentures for Global Health (Woodson, 2014). 
A very recent review gives examples of Training in Tropical Diseases (TDR), approaches and 
contributions to drug discovery research and development (R&D), and the optimization of known 
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treatments against the background of immense changes in the R&D landscape for infectious diseases 
of poor people (Olliaro et al., 2015). 
Between 1975 and 1990, only ten drugs were registered for tropical diseases: benznidazole and 
nifurtimox for Chagas‟ disease; pentamidine for human African trypanosomiasis (HAT); oxamniquine 
and praziquantel for schistosomiasis; ivermectin for onchocerciasis; pyrazinamide, halofantrine and 
mefloquine for malaria; and albendazole for soil-transmitted nematodes (STNs). It is important to note 
that all these drugs, except halofantrine, are still in use. All of these drugs were developed 25 to 40 
years ago; however, they continue to be the cornerstones of strategies in disease control.  
Drug development between the public and private sector has been rare in the last years, but there 
are some cases. Mefloquine was studied in collaboration between the United States Army Medical 
Research and Development Command, La Roche, and TDR. 
During the 2000-2011 period, TDR participated actively in the development of three products, 
including an injectable artemotil [arteether], rectal artesunate for malaria and oral miltefosine for 
visceral leishmaniasis [VL]), and played an important role in contributing to the identification and 
development of a number of other drugs, such as artesunate-amodiaquine and artesunate-mefloquine 
for malaria and paromomycin for VL. 
Trouiller et al. (2002) reported the development of six products for stage 2 of human African 
trypanosomiasis, eflornithine for visceral leishmaniasis, liposomal amphotericin B for severe malaria, 
injectable artemether for uncomplicated malaria, and atovaquone and rifapentine for tuberculosis. 
TDR provided the coordination and funding for the pivotal clinical trials that supported their 
registration. Currently, TDR continues to fund research on new targets, screening, identification of 
leads, and development of new candidates.  
The current challenges are completely different from those at TDR‟s start. Now, there are different 
players and proportionally more funding than before, and the primarily public or nonprofit 
organization, devoted to research and the search for new drugs and diagnostics, still requires 
coordination to optimize resources. This active environment requires new and innovative solutions, 
but there is a need for continuity and also an adaptation to produce adequate results (Olliaro et al., 
2015). 
The new trends in the last decades suggest that the most innovative strategy at this time should be 
the use of nanotechnology in the search of new uses for old pharmaceuticals or new development of 
innovative and intelligent nanomedicines for neglected diseases.  
 
2. Nanostructures most commonly used in  neglected diseases 
The relevance of nanostructures in biomedical applications is enormeous. Then, the characteristics 
and aspects of these nanostructures will be briefly described in this section (Figure 2). 
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2.1. Liposomes 
Liposomes are sphere-shaped vesicles formed by phospholipid bilayers reported in the mid-60s that 
have currently made their way to the market. Currently, they have progressed from conventional 
vesicles to „second-generation liposomes‟, in which long-circulating liposomes are obtained by 
modulating the lipid composition, size, and charge of the vesicle and functionalized with molecules, 
such as glycolipids or sialic acid. Liposomes are promising intracellular delivery systems for antisense 
molecules, ribosomes, proteins and/or peptides, and DNA. Probably the most important function of 
liposomes is to promote targeting of particular diseased cells within the disease site. Liposomal drugs 
also exhibit reduced toxicities and retain enhanced efficacy compared with free complements 
(Akbarzadeh et al., 2013). Examples of liposomal formulation in the treatment of negelted diseases are 
shown in Table 3. 
 
2.2. Polymeric and natural macromolecule nanoparticles 
Polymeric nanoparticle-based materials have gained an important position due to advancements in 
polymer science and technology. These nanoparticles are solid colloidal systems in which the 
therapeutic agent is dissolved, entrapped, encapsulated, or adsorbed onto the constituent polymer 
matrix (e.g.,  nanosphere-matrix systems in which the drug is dispersed throughout the particles); they 
are nanocapsules (vesicular reservoir systems in which the drug is confined to an aqueous or oily 
cavity surrounded by a single polymeric membrane). Several polymers such as poly(lactide-co-
glycolide) (PLGA), polylactide (PLA), polyglycolide, polycaprolactone (PCL), poly(d,l-lactide), 
chitosan, and PLGA–polyethylene glycol (PEG) have been developed for passive and ligand-targeted 
delivery of therapeutic moieties (Prabhu et al., 2015) (Table 4). 
 
2.3. Solid lipid nanoparticles and nanostructured lipid carriers  
Solid lipid nanoparticles (SLN) are nanoparticles prepared from a lipid matrix that is solid at body 
and room temperature, stabilized by suitable surfactants. Nanostructured lipid carriers (NLC), i.e., 
nanoparticles composed of a mixture of a solid and a liquid lipid whose lipid matrix is solid at room 
and body temperature, are a second generation of solid lipid-based colloidal carriers, with improved 
stability, drug encapsulation ability and controlled drug release (Figure 3). Furthermore, in vitro 
tolerability of SLN and NLC appears to be much higher than that of polymeric nanoparticles (Hirlekar 
et al., 2011; Doktorovova et al., 2014; Dolatabadi et al., 2015; Islan et al. 2016) (Table 3). 
 
2.4. Nanoemulsions 
Nanoemulsions are nano-sized emulsions that are manufactured for improving the delivery of 
active pharmaceutical ingredients for nelgelted disease therapies (Table 5). The ability of 
nanoemulsions to dissolve large quantities of hydrophobics, along with their mutual compatibility and 
ability to protect the drugs from hydrolysis and enzymatic degradation, makes them ideal vehicles for 
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the purpose of parenteral transport (Lovelyn and Attama, 2011; Kela and Kaur, 2013; Jaiswal et al., 
2015).  
 
2.5. Nanocrystals  
Nanocrystals from bulk pharmaceuticals or chemicals are carrier-free colloidal delivery systems in 
the nano-sized range that are important for poorly soluble drugs. Nanocrystals exhibit several features 
including enhancement of saturation solubility, dissolution velocity and adhesiveness to surface/cell 
membranes. Many different methologies are applied for nanocrystal production, including 
precipitation, milling, high pressure homogenization and combination methods such as Nano-Edge™, 
SmartCrystal and precipitation-lyophilization-homogenization (PLH) technology. Nanocrystals for 
oral administration were reported to be useful for improving in vivo performances, i.e., 
pharmacokinetics, pharmacodynamics, safety, and targeted delivery (Table 5). An interesting benefit 
of drug nanocrystals is that they can provide smaller dose administration to achieve moderate blood 
level and thus reduce the side effect from giving a larger dose. Furthermore, nanocrystal drugs can be 
delivered through various routes of administration such as oral, parenteral, ocular, pulmonary and 
dermal delivery (Durán et al., 2010a; Salazar et al., 2012; Bhuyan et al., 2014; Junyaprasert and 
Morakul, 2015). 
 
2.6. Metal nanoparticles 
Metal nanoparticles, which are a cluster of metal atoms, play an importat role due to their unique 
optoelectronic and physicochemical properties, which depend strongly on their size, shape, 
crystallinity and structure. These properties have led to a wide range of potential applications in 
diverse areas such as molecular diagnostics, electronics, catalysis, drug delivery or sensing. Different 
physical and chemical methods have been employed for the synthesis of metal nanoparticles. The use 
of biological organisms in the synthesis and assembly of nanoparticles has received increasing 
attention, since they are a clean, cost-effective and efficient synthesis technique (Cauerhff and Castro, 
2013). In the biomedical sector especially, the metal nanoparticles will play a crucial role in 
diagnostics, drug delivery, cosmetics, agriculture, band aids, etc. Although metallic/metal 
nanoparticles are important in remediation through pollution absorption, water filtering, disinfection, 
etc., the best example is the use of inorganic nanoparticles as antimicrobial agents. Silver 
nanoparticles are being exploited as new generation antimicrobials because of their significant activity 
against many types of pathogens including multidrug-resistant organisms (Islan et al., 2015). Although 
a concern due to large applications, their potential toxicities and the properties forcing such toxic 
responses must also be studied and understood (El-Nour et al., 2010; Durán et al., 2010b, 2011; Rai 
and Durán, 2011; Rai et al., 2014ab; Castro et al., 2014). In this area, there have been many 
misunderstandings about silver nanoparticle characterization, which sometimes has made it hard to 
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correlate the biological activities with the structure (Durán et al., 2016c). Some examples of the use of 
metallic nanoparticles for the therapy of neglected diseases are listed in Table 6. 
 
2.7. General comments about previous knowledge related to neglected diseases treated 
through nanotechnology 
Since 2007, there has been concern about the slow development of new antiparasitic drugs, and 
suggestions have been made for an effective management of the current drugs using new strategies, 
including the modulation of their delivery. Accordingly, Date et al., (2007) published a review 
focusing on  biological and biopharmaceutical topics considering the design of a delivery strategy to 
treat parasitic infections such as leishmaniasis, malaria, and trypanosomiasis. They pointed out the 
importance, at that time, of polymeric nanoparticles, liposomes, lipid nanoparticles including lipid 
drug conjugates (LDC) and solid lipid nanoparticles. Pimentel et al. (2007) emphasized the potential 
of liposomes and polymeric nanocapsules acting on malaria parasites and as a promising alternative 
for malaria control and treatment.  
However, after 30 years of research in the field of antileishmaniasis, currently AmBisome 
(liposomes) is the only drug delivery system used against the visceral form, and most of the 
experimental development only involves parenteral administration (Meyerhoff, 1999). 
Durán et al. (2009) commented that for a real development in this area, there is a need for 
significant funding from private and public partners to apply nanobiotechnology to the treatment of 
neglected diseases. Their review focused on neglected diseases (e.g., malaria, schistosomiasis, 
leishmaniasis, trypanosomiasis, tuberculosis, leprosy, filiarasis, and onchocerciasis), where many 
different nanomaterials, such as polymeric nanoparticles, liposomes and nanostructured lipid carriers, 
have been applied. But again, the negative aspects were that up to 2009, very few nanomaterials had 
been used in clinical tests. 
Different aspects of nanotechnology applied to neglected diseases were discussed by El-Tonsy 
(2010). He pointed out that nanomedicine is a wide area with applications in many aspects, such as 
diagnosis, monitoring, treatment and control of biological systems in leishmaniasis, toxoplasmosis and 
malaria. Similar comments pointed out that drug delivery formulations involved low-cost research 
compared to that for the development of new molecules (Qureshi et al., 2011). Khalil et al. (2013) 
described the roles of colloidal drug carriers, such as polymeric nanoparticles, liposomes, and solid 
lipid nanoparticles, in optimizing the delivery of drugs against neglected diseases. Malaria was one of 
the privileged diseases using these particulate carriers as vehicles for the delivery of active 
compounds. 
Since several nanoscale materials in delivery systems have already proved to be efficicient in 
animal models for the treatment of malaria, strategies to release antimalarials using different 
nanocarriers (e.g., solid lipid nanoparticles, liposomes, and nano- and microemulsions and polymer-
based nanocarriers) and mechanistic aspects that direct their targeting to Plasmodium spp.-infected 
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cells were discussed by Santos-Magalhães and Mosqueira (2010). Singh (2012) also published  an 
interesting chapter that highlights the available antimalarial therapies, as well as the potential benefits 
of nanotechnology platforms in malaria treatment. A review by Umeyor et al. (2013) presented various 
possibilities in malarial chemotherapy, as well as an important and detailed screening of different 
nanoparticle drug release systems and the new aspects in the delivery of antimalarial drugs in that 
period. In a similar way, Aditya et al. (2013), Ranjita et al. (2011) and Banyal et al. (2013) discussed 
the importance of nanomedicine in the treatment for drug-resistant parasites in malaria as well as in 
tuberculosis.  
A review by Kaur et al. (2014) discussed the entire global scenario of tuberculosis by introducing 
promising nanocarrier delivery systems or by modifying existing systems such as chemotherapy 
protocols for tubercuosis. This review pointed out that nanotechnology provided an immense 
possibility for the design of a new, minimum-dose, and effective treatment system to control 
tuberculosis. In 2014, it was suggested that inhaled formulations could be promising for pulmonary 
and systemic non-pulmonary diseases. These nozzles can produce nanocomposite particles in one step, 
and their spray-drying system is suitable for scaling up. Nanocomposite particles are useful for 
improving drug absorption and delivery efficacy against alveolar macrophages. In addition, recent 
studies on several pulmonary diseases (tuberculosis, lung cancer, cystic fibrosis, pneumonia, and 
others) and related inhaled formulations have also been reviewed (Ozeki and Tagami, 2014). 
Ali et al. (2014) reported the connotations of drug delivery systems in targeting lymphatic filaroids 
or wolbachia and systemic microfilaria (e.g., liposomes and solid lipid nanoparticles for the treatment 
of lymphatic filariasis).  
One review discussed several nanocarriers (e.g., solid lipid nanoparticles, liposomes, polymeric 
nanoparticles, inorganic nanoparticles, etc.) on the basis of approaches that have been applied in the 
literature and in the clinic to combat the different challenges faced by antiviral therapy. Important 
developments in this area with solid lipid nanoparticles, liposomes, polymeric nanoparticles and 
inorganic nanoparticles have been reported for lectin receptors, and cell-penetrating peptides for site-
specific delivery of antiviral agents (Mehendale et al., 2013). 
The advances in chemoinformatics, genomics, bioinformatics and proteomics have brought great 
opportunities for the fast and cost-effective discovery of new bioactive compounds against these 
tropical diseases. Neves et al. (2015) reviewed the most important contributions of nanomaterials in 
drug discovery and in the treatment of schistosomiasis, and pointed out how integration promotes 
specific strategies (e.g., virtual screening) and may contribute to the development of new 
schistosomidal leads, mainy through the identification of new biologically active chemical scaffolds 
and optimization of nanoparticle structures with previously known activity. 
 
3. Considerations and analysis of nanotechnology applications in neglected diseases 
10 
 
3.1. Malaria 
Malaria in humans is caused by five Plasmodium species: P. malariae, P. knowlesi, P. ovale, P. 
falciparum, and P. vivax. In general, the current research is focused on the latter two strains, because 
they are the deadliest and most widespread. Many efforts to control and eradicate malaria through 
insecticides and antimalaria treatments (e.g., artemisine-combined therapies) contributed to a 42% 
decrease in malaria death. Benelli and Mehlhorn (2016) stated that the emerging scenario highlights 
that a more effective and green control of mosquito vectors, especially highly invasive species, such as 
Aedes aegypti and Aedes albopictus, is crucial. However, one of the challenges is still drug resistance, 
and currently no effective malaria vaccine exists (Table 2). The only malaria vaccine in phase III 
testing is the Glaxo Smith KlineRTS, S/AS01 vaccine, but its vaccine efficacy is only ~30% (Siu and 
Ploss, 2015). 
An important challenge to malaria prevention and control is the mosquito strains resistant to 
synthetic pesticides. Based on the malaria disease complexity, innovative methods will be welcome to 
combat growing drug resistance among parasites. Effective malaria treatment is critical for controlling 
the disease. Some of the currently used antimalarials are chloroquine, artemether, arteether, artesunate, 
artemether/lumefantrine, sulphadoxine/pyrimethamine, chlorproguanil/dapsone, mefloquine, 
atovaquone/proguanil and primaquine (Date et al., 2007; WHO, 2014). But the current therapy has 
drawbacks such as Plasmodium resistance to drugs, poor bioavailability and extremely low solubility 
in both aqueous media and oils. The main drawback is related to arteminsins and poor patient 
compliance at high doses, and also to the need for long-term treatment and high toxicity (Date et al., 
2007; Isacchi et al., 2012; Tripathy and Roy, 2014). 
To overcome these undesirable and adverse effects, it is possible to encapsulate antimalarial drugs 
in liposomes. This colloidal carrier protects the drug from degradation with controlled release and 
fewer adverse effects (Date et al., 2007). 
Since the late 1970s, antimalarials encapsulated in liposomes have been studied to decrease the 
toxicity of the drug. In experimental murine malaria Pieson et al. (1979) observed that liposome 
encapsulation reduced primaquine toxicity 3.5 times compared with the free drug. In another study in 
mice, using radiolabeled free and liposome-entrapped primaquine, these researchers demonstrated that 
the incorporation of primaquine in liposomes reduced the accumulation of the drug in nontarget tissues 
(e.g., lungs, heart, kidneys, and brain), thereby reducing primaquine toxicity. Moreover, primaquine 
encapsulated in liposomes was detected mainly in spleen and liver, giving better hypnozoitocidal 
efficiency (Pieson et al., 1979, 1982). 
Primaquine in liposomes depend on lipid composition, drug-to-lipid incubation ratio, internal 
buffer capacity, and the presence of cholesterol and liposome charges. Lyophilized and sterilized 
(gamma irradiation) liposomes exhibit long-term stability and sterility. Low chemical degradation is 
obtained when the pH gradient is maintained (Stensrud et al., 2000). 
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Other nanoformulations of primaquine with an appropriate drug carrier system have been studied to 
enhance bioavailability, increasing its activity with fewer doses and lower toxicity. Owmoyo et al. 
(2014) designed, synthesized and characterized primaquine-loaded solid lipid nanoparticles (SLNs) 
(PQ-SLNs). The average particle size, charge (zeta potential), drug loading, and encapsulation yield of 
the PQ-SLNs were 236 nm, +23 mV, 14% and 75%, respectively. The particle size was small enough 
to provide absorption in the gastrointestinal tract. This small size and the moderately positive surface 
charge could trigger an elevated concentration of primaquine in the liver. The nanoformulated PQ was 
20% more effective compared with the conventional oral dose in Plasmodium berghei-infected Swiss 
albino mice. Since the drug was highly effective against hypnozoites concentrated in the liver, one of 
the stages of malaria, this formulation was found to be effective for antimalarial drugs. Chloroquine is 
a common drug for malaria treatment, but at present showing resistance in most parts of the malaria 
endemic regions. To overcome this problem, Owais et al. (1995) studied the liposome/chloroquine 
carriers in drug-resistant malaria treatment. They tagged antibody on the liposome/chloroquine against 
infected erythrocytes and assayed their efficacy in chloroquine-resistant P. berghei infection in mice. 
These liposomes recognized only the infected cells and not normal erythrocytes. This nanostructure 
was active when applied intravenously at 5 mg/kg body weight per day. 
The animals with chloroquine-resistant P. berghei infections were completely cured (75% to 90%). 
The reasons for parasite resistance to chloroquine were attributed to the enhanced efflux of 
chloroquine from the resistant parasites, hindering intracellular concentrations at toxic levels. These 
results indicated the effectiveness of liposomes with chloroquine against malaria-infected 
erythrocytes, possibly curing chloroquine-resistant malarial infections with low doses. 
There is clinical evidence of the effectiveness of chloroquine-chlorpheniramine coadministration in 
overcoming drug resistance. Chloroquine resistance is possibly due to effects on P-glycoprotein (Pgp)-
mediated drug efflux, which makes attainment of adequate drug levels impossible. Nzekwe et al. 
(2015) included a P-gp inhibitor, chlorpheniramine, and chloroquine in a lipid-based nanoparticle 
carrier with the aim of ensuring that adequate drug levels were attained, so as to overcome drug 
resistance. They concluded that coformulation of chloroquine and chlorpheniramine in lipid-based 
nanoparticles was feasible using a simple hot emulsion-dilution method. Further studies will be 
devoted to toxicological tests and in vivo testing in both resistant and sensitive strains of Plasmodium 
falciparum. 
Other strategies to deliver chloroquine using nanocarriers have been developed. Tripathy et al. 
(2012, 2013) developed chitosan-tripolyphospate (CS-TPP) nanoparticles (NPs) combined with 
chloroquine. Chitosan is a natural polysaccharide that currently is extremely useful for the synthesis of 
nanoparticles and is widely studied. Chitosan nanoparticles are prepared by ionotropic gelation 
between chitosan and sodium tripolyphosphate. The synthesis of chitosan-tripolyphosphate 
nanoparticles conjugated to chloroquine was effective against P. berghei infection in Swiss mice and 
more potent than only chloroquine to attenuate the parasitemia and host pathology also. Lymphocytes 
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are also susceptible to lethal P. berghei infection due to a significant oxidative stress that leads to 
decreased antioxidant status of the mammalian cells. This nanochloroquine formulation was able to 
increase protection of lymphocytes. These researchers suggested that this combination is more 
prospective than free chloroquine for protecting the host from parasitic infection by diminishing free 
radical generation, lipid oxidation, and DNA damage probably by increasing antioxidant levels. It is 
possible to conclude from this study that this nanopharmaceutical may be administered as a potent 
therapeutic agent compared to free chloroquine (Tripathy and Roy, 2014). 
Artemisinin, isolated from Artemisia annua L., a plant derived from traditional Chinese medicine 
(qinghaosu), has been used for 2,000 years in the treatment of malaria (Isacchi et al., 2011; Tripathy 
and Roy, 2014). It is an extremely active antimalarial drug, active even against chloroquine- and 
quinine-resistant Plasmodium sp. However, its therapeutic efficiency is limited due to its low 
bioavailability. To overcome this drawback, Isacchi et al. (2011) prepared conventional artemisinin-
loaded and PEGylated liposomes. In both cases, the encapsulation efficacy was >70%; diameters were 
also similar (130–140 nm). Both liposomal formulations exhibited longer blood-circulation time than 
free artemisinin. There was a 5-fold increase in the half-life of artemisinin in the case of PEGylated 
liposomes. 
Other formulations were designed with artemisinin and derivatives. Free artemisinin, or combined 
with curcumin as before, was encapsulated through a conventional way or in PEGylated liposomes. 
Artemisinin alone had an effect on parasitaemia levels only 7 days after the initiation of treatment. On 
the contrary, treatments with conventional artemisinin-loaded liposomes or artemisinin-loaded 
PEGylated liposomes with or without the presence of curcumim appeared to have a short-term 
antimalarial effect. Besides, all formulations showed low variability in artemisinin plasma 
concentrations, compared to the free one, showing a regular antimalarial effect over time (Isacchi et 
al., 2012). 
Artemether (a derivative of artemisinin) and lumefantrine are well-accepted in combination therapy 
for uncomplicated malaria treatment. Artemether first acts on the malaria parasites and reduces the 
parasite burden instantly, and later lumefantrine acts on the remaining parasites or the parasites that 
come out of hibernation, which are mostly merozoites. However, the current formulation is available 
as tablets for oral administration and has several pharmacokinetic problems such as drug degradation 
in the gastrointestinal tract and low absorption (Parashar et al., 2014). Therefore, Parashar et al. (2014) 
designed and prepared artemether and lumefantrine co-loaded injectable nanostructured lipid carriers. 
Artemether and lumefantrine co-loaded NLCs had a hydrodynamic diameter of ~145 nm with a 
surface charge of -66 mV. This formulation showed effective antimalarial activity with respect to 
progression of parasitemia and survival time in the treatment of P. berghei-infected mice. 
Semisynthetic derivatives of artemisinin, artemether and arteether (ART) have also been studied as 
treatments for uncomplicated P. falciparum malaria in most malaria-endemic countries. The problem 
associated with these derivatives includes its poor aqueous solubility and low stability in the gastric 
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medium (they decompose at gastric pH 1.2 at high temperature or with long incubation), which results 
in poor bioavailability. Nanoemulsions (NEs) loaded with arteether have been prepared using a high 
pressure homogenization (HPH) technique with the aim of improving arteether solubility and thus, its 
bioavailability. Maximum drug loading was achieved up to 93.0 ± 7.4% with a globule size of 156.0 ± 
10.2 nm and zeta potential of -23.3 ± 3.4 mV. The ART-NEs were found to be stable in terms of 
globule size and size distribution at different pH values, and the in vitro release profile showed 62% 
drug release within 12 h. Therefore, ART-NE can be a promising oral delivery system for ART 
(Dwivedi et al., 2015). 
Innovative methods are a welcome resource to combat growing drug resistance among malaria 
parasites. Hemozoin nanocrystals can be used to detect and mechanically kill the malaria parasite in 
theranostic applications. The blood-stage malaria parasite uses hemoglobin as a nutrient source, 
releasing large amounts of potentially toxic heme, which generates reactive oxygen species, causing 
death of the parasite. To circumvent this internal toxicity, the parasite packages the heme groups into 
biochemically inert nanocrystals called hemozoin particles that are located in food vacuoles inside the 
parasite. The high optical absorbance of the hemozoin nanocrystal can be used to generate transient 
localized vapor nanobubbles in response to a short laser pulse, and this vapor nanobubble generation 
around hemozoin supports the efficient detection and destruction of malaria parasites in a theranostic 
procedure at the nanosecond scale. Laser-induced nanobubbles acting on human blood in vitro 
demonstrated a destruction of up to 95% of parasites after a single procedure, with 8-fold better 
parasiticidal efficacy compared to standard chloroquine treatment, being highly selective against 
malaria-infected red cells and not against uninfected erythrocytes (Hleb and Lapotko, 2014). 
The use of nanocarrier systems, liposomes, nanostructured lipid carriers, polymeric nanoparticles, and 
nanocrystals shows promising results in the treatment of malaria, with low toxicity and high efficacy, 
along with prolonged release associated with a reduced number of doses (Durán et al., 2009; Hleb and 
Lapotko, 2014; Najer et al., 2014) (Figure 4). 
Murugan et al. (2015a, 2016ab) reported that silver nanoparticles were effective against Plasmodium 
falciparum and its vector Anopheles stenensi. However, in these cases, the main nanostructure is not 
silver nanoparticles but silver chloride nanoparticles, as in many biogenic syntheses with plants 
(Durán et al., 2016c). Using biogenic gold nanoparticles, Subramaiam et al. (2016) reported interesting 
results against malaria.  
 
3.2. Leishmaniasis 
Leishmaniases are vector-borne zoonotic diseases caused by various species of protozoa of the 
genus Leishmania. These pathogens are transmitted by sandflies (e.g., phlebotomine) and infect 
humans that are exposed to ecosystems where the vectors and reservoirs coexist. Anthroponotic cycles 
have been documented for some species of Leishmania and for defined geographical areas such as that 
of Leishmania donovani in the Indian subcontinent and Leishmania major in Afghanistan. 
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Leishmaniases are prevalent in tropical and subtropical areas, with two million new cases occurring 
yearly. Visceral leishmaniasis (VL) is caused by L. donovani in the Indian subcontinent and East 
Africa and by L. infantum in other parts of Asia, Europe, Africa and the New World (formerly referred 
to as L. chagasi). 
Tegumentary leishmaniasis (TL) is caused by many species of parasites: L. major, L. tropica, L. 
aethiopica and sometimes L. infantum in the Old World and L. (Viannia) braziliensis, L. amazonensis, 
L. (V.) guyanensis, L. (V.) panamensis, L. mexicana, L. pifanoi, L. venezuelensis, L. (V.) peruviana, L. 
(V.) shawi, and L. (V.) lainsoni in the New World. Among species causing TL, different species of 
subgenus Viannia and L. amazonensis are found from Mexico to Argentina, and the largest variety is 
present in Brazil, mainly in the Amazon region. L. mexicana is present in Mexico and some Central 
American countries (Lindoso et al., 2012). 
Accordingly, the control of these parasites is of important public health concern. The development 
of new technologies is imperative to deal with VL to control epidemics and obviously to reduce its 
impact on society (Marinho et al., 2015). The difficulty of assessing these strategies has been due to 
the gap between intervention and the control of transmission, which has only been evaluated by three 
studies, namely, indication and epidemiologic impact of linking intervention and epidimiologic 
impact. Most recent treatments for VL using miltefosine and paramomycin have not been evaluated 
enough and should be evaluated in different scenarios (e.g., epidemiological ones). In the future, 
investigations should consider a longer time horizon, in such a way that the infectious disease 
properties and peculiarities of VL could be efficiently expressed and accounted for (Marinho et al., 
2015). 
Leishmaniasis accounts for the second highest burden of parasitic disease after malaria. Depending 
on the causative species of the parasite, different types of the disease can occur. The two most 
common are visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). VL is the most severe one, 
being fatal in some cases, most of the time enhanced by parasite migration to vital organs resulting in 
several strong and harmful symptoms  such as hypergammaglobulinemia and pancytopenia. On the 
other hand, the cutaneous infection is the most common form of the disease and can exhibit a high 
range of manifestations such as cutaneous nodules and gross mucosal tissue destruction. Moreover, it 
had been reported that CL causes high morbidity levels because of the continued presence of skin 
ulcers and the terrible psychological effects, especially in children patients (Bern et al., 2008).  
Parenteral administration of pentavalent antimony compounds still represents the most common 
therapeutical option for all leishmaniasis forms (Desjeux, 2004). However, resistance and high 
frequency of side effects are major problems with these drugs. Amphotericin B (AmB), a highly 
hydrophobic drug, is the most used second-line therapy. The drug is highly active, but its clinical use 
is limited due to its toxicity and the high treatment cost (Rodrigues Caldeira et al., 2015). Later, its 
liposomal formulation (LAMB) displayed a significant reduction in treatment toxicity. This was 
followed by the introduction of miltefosine (MF) and paromomicyn (PM) in the clinical market. 
15 
 
LAMB continued being the first choice because of its effectiveness and low side effects. However, the 
excessive high cost of the treatment (AmBisome®, Astellas Pharma US, Inc.) represents a big 
limitation for its widespread use, especially for the majority of the population in poor countries. Some 
different formulations of these drugs have been prepared, but VL treatment still relies on the 
traditional AmB administration worldwide. Despite its severe side effects, AmBisome® has been 
recommended as first-line treatment of leishmaniasis by the World Health Organization Expert 
Committee on the Control of Leishmaniasis (Balasegaram et al., 2012). Moreover, there has been a 
similar tendency for CL treatment. Currently, meglumine antimoniate (Glucantime) is the first drug of 
choice for local or systemic injection and it has been used for more than four decades despite not being 
approved by the FDA and presenting high toxic effects on human organs (Momeni et al., 2013). 
In this scenario, there is an urgent need for new effective drugs or formulations that allow (in a first 
step) a wide reduction of toxicity. Patients with an advanced disease present physiologic problems in 
several organs as usual consequence. If the established cure for the disease is as aggressive as the 
parasite infection, the whole treatment has no sense. Another point to take into consideration is the 
high cost of the treatments. As mentioned before, leishmaniasis is endemic especially in those regions 
with development problems and with a big population of poor families. It is clear that an excessively 
expensive treatment like AmBisome® is not a satisfactory alternative despite its effectiveness and well 
tolerance by VL patients. In this part of the review, we will show why nanotechnology is a tool with 
the potentiality to solve these problems in leishmaniasis treatment. 
Many articles of clinical relevance envisioning promising outcomes for leishmaniasis patients have 
been published in recent years. Nanomedicines generally consist of nanoparticulate drug delivery 
systems based on liposomes, solid lipid nanoparticles, polymeric nanoparticles and others. These 
nanocarriers enhance drug efficacy, while reducing drug toxicity by optimizing pharmacokinetics and 
pharmacodynamics (Henriques et al., 2014; Moreno et al., 2015) (Figure 5).  
Antimonial liposomes against visceral and cutaneous forms of leishmaniasis have been studied 
since 1984. As mentioned before, AmBisome and Amphotec are the most used commercial 
formulations for VL. As a consequence of liposomal encapsulation, toxicity of amphotericin B was 
reduced by a factor of 50- to 70-fold. The problem with AmBisome is still its cost (estimated at 800 
euros per 1 injection per day) (Durán et al., 2009). Many efforts have been made by modulating 
liposome composition and structure in order to achieve better biocompatibility and encapsulation 
rates. Besides, different active principles were tested in liposomal systems either as encapsulated drugs 
or lipids with some therapeutic influence. Hexadecylphosphocholine (HePC) is a perfect example of a 
phospholipid that, being an important structural ingredient in liposome formulation, has an effective 
antiparasitic activity against leishmaniasis. The liposomal form of HePC showed to be less toxic than 
plain phospholipid (Papagiannaros et al., 2005). In contrast, there are not many reports about the uses 
of liposomes for CL. Glucantime® was one of the effective drugs tested for encapsulation in 
liposomes, but its hydrophilic nature allows only low encapsulation rates (Ribeiro et al., 2008). Later, 
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a freeze-drying double emulsion (FDE) method was utilized to prepare liposomes with Glucantime®, 
miltefosine and paromomycin payloads. Formulations were prepared with 90% encapsulation 
efficiency (EE). However, a common characteristic of the FDE method is the bimodal size distribution 
of the liposomes, which poses a problem at the moment of sterilizing the formulation. After the 
sterilization by filtration, the EE was reduced to 50%, which is still acceptable for hydrophilic drugs. 
Moreover, in vivo tests showed a potential therapeutic effect against Leishmania major infection for 
CL treatment (Momeni et al., 2013). More recently, another liposomal formulation was prepared by 
the fusion method plus homogenization for the encapsulation of Glucantime®. The advantage of this 
method is based on its simplicity and no use of organic solvents, exhibiting an EE of around 50%. The 
final formulation was tested for topical application by cell diffusion studies using mouse skin and 
vertical Franz cell diffusion. The results indicated that only 1% of the drug penetrated through the 
skin. This is a key point since Leishmania amastigotes live in the macrophages deep the in dermal 
layer (Moosavian et al., 2014).   
 Accordingly, the anticancer drug doxorubicin encapsulated in immunoliposome (immunodoxosome) 
produced total parasite elimination after 45 days compared with a similar dose of the free drug 
(doxosome). Both immunodoxosome and doxosome exhibited less toxicity than the free doxorubicin, 
showing the potential of encapsulated doxorubicin as an effective therapy against leishmaniasis 
(Mukherjee et al., 2004).  
Another nanocarrier that has gained interest in the last decade consists of solid lipid nanoparticles. 
Although the application of SLNs in leishmaniasis is still not as important as liposomal formulation, 
the number of articles on this subject has been growing in the last years. For example, it has been 
demonstrated that this system allows the high encapsulation efficiency of hydrophobic molecules like 
AmB (Jung et al., 2009). SLNs were prepared with AmB for oral administration, since the avoidance 
of intravenous route could prevent the toxic effects of this drug. However, AmB is not absorbed 
orally, and that is why this nanoformulation was taken into consideration. In in vivo tests, these 
authors demonstrated a 40-time increment in AmB bioavailability in comparison with free AmB. 
However, they could not elucidate the SLN absorption mechanism (Amarji et al., 2007). Recently, 
Lopez et al. (2012) reported a comparative study between liposomes and SLN formulation with the 
incorporation of a dinitroaniline, oryzalin (ORZ). This compound is a microtubule inhibitor with 
selectivity to bind only to parasite tubulin. In vivo studies in a murine model of visceral leishmaniasis 
have shown no significant differences between both formulations. Nevertheless, liposomal and SLN 
formulations led to a significant parasitic burden reduction in liver and spleen as compared to the 
control group (84% to 91%) and similar to that of Glucantime® (Lopes et al., 2014). Like many active 
principles, ORZ causes high toxicity in several organs. It was also demonstrated that the encapsulation 
of this drug in SLNs decreased its cytotoxicity (Lopes et al., 2012). In another study, paromomycin 
was incorporated into SLNs in order to enhance skin penetration of the drug for CL treatment. 
Paromomycin clinical use is restricted because of its poor capability to penetrate skin layers. Despite 
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the drug hydrophilic nature, stearic acid nanoparticles were formulated with an EE of 39%, which is a 
reasonable value for this kind of molecule. Then, these drug delivery systems showed a sustained drug 
release profile for more than 24 h. It is interesting to notice that molecules of hydrophilic nature can be 
incorporated into SLNs (Ghadiri et al., 2011).  
In addition to these SLN systems designed for the delivery of pharmaceutical molecules against 
leishmaniasis, it is worth mentioning that in other scientific studies SLN formulations were tested for 
the design of vaccines. Among the several antigens potentially capable of inducing protective 
immunity, cathepsin L-like cysteine proteinases (CPs) have received considerable attention for 
experimental visceral leishmaniasis. CPs are commonly found from prokaryotes to mammal‟s 
organisms. In Leishmania, CPs are involved in parasite survival, replication and the onset of disease, 
which makes them attractive vaccines and/or drug targets. However, the major obstacle for this kind of 
vaccine is its quick degradation. In this sense, Doroud et al. designed a SLN formulation for the 
delivery of P-DNA for CPs type I and II. P-DNAs must reach the nucleus of the target cells in order to 
express the foreign gen. In this case, SLNs worked as a protector yield for DNA preventing its 
degradation and also modulating the release profile. The cytotoxicity and gene expression effect of 
SLN-pDNAs was evaluated and compared to linear PEI (25-kDa)-pDNA polyplexes as a standard 
control (Doroud et al., 2010). Furthermore, in a consecutive research article, the incorporation of 
recombinant CPs (type 1) into SLNs to be utilized as a vaccine against Leishmania major infection in 
C57BL ⁄ 6 mice was reported. After intraperitoneal vaccination, an antigen-specific T-helper type 1 
(Th1) immune response was induced compared to control groups. Lymph node cells from immunized 
mice displayed lower parasite burden, higher IFN-c, IgG2a, and lower IL-4 production, indicating that 
robust Th1 immune response was induced (Doroud et al., 2011). 
Colloidal nanocarrier polymeric nanoparticles also exhibit relevant properties such as stability, 
biodegradability and high EE for many active molecules. In this sense, anti-leishmania drugs are not 
excluded from the list. PLGA NPs were prepared for β-aescin encapsulation. In vitro results 
demonstrated that the drug incorporation in the polymeric nanocarrier allowed a reduction in the 
cytotoxicity and maintenance of the antileishmanial efficacy (Van de Ven 2011). In addition, a recent 
study evaluated the use of AmB loaded PLGA NPs as a drug delivery system. In vivo tests showed 
high uptake of nanoparticles in the lungs, liver and spleen, demonstrating the potentiality of the 
formulation for anti-leishmania treatments (Souza et al., 2015).  
Studies have probed the effectiveness of silver nanoparticles as an alternative therapy for 
leishmaniasis, specifically by subcutaneous intralesional administration for CL. Silver NPs can be 
synthesized by chemical, physical or biological methods (Durán et al., 2011). Biological synthesis is 
an eco-friendly alternative and is carried out by using microorganisms, enzymes, and plants. Besides, 
these synthesis methods generate more effective NPs in medicinal applications due to their surface 
biocoatings (Prasad et al., 2011). In addition, both chemically and biologically synthesized NPs were 
compared first by in vitro experiments against Leishmania amazonensis promastigotes. Biologically 
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generated silver NPs (Bio-AgNPs) showed to be four times more effective than chemically generated 
ones (Chem-AgNPs). Then in vivo studies in infected mice demonstrated that a Bio-AgNP dose was 
equally effective as 300-fold higher doses of amphotericin B, and more effective than 3-fold higher 
doses of Chem-AgNP. Furthermore, no hepato- or nephrotoxicity was detected in comparison with 
amphotericin B and Chem-AgNPs (Rossi-Bergmann et al., 2012).  
 
3.3. Schistosomiasis 
Schistosomiasis is a disease caused by parasitic flatworms of the genus Schistosoma, with three 
species (S. mansoni, S. haematobium, and S. japonicum) accounting for the majority of human 
infections. These parasites cause a chronic and often debilitating infection that impairs development 
and productivity, and exposure to these parasites is unfortunately strongly linked to extreme poverty. 
Recent estimates indicate that in around 80 endemic countries (e.g., sub-Saharan Africa, the Middle 
East, the Caribbean, and South America) more than 250 million people are infected annualy, resulting 
in 200,000 deaths (Neves et al. 2015). Unfortunately, lack of knowledge related to the disease, 
deficient sanitation, and the absence of effective health policies promote the spread of schistosomiasis 
in endemic countries. Praziquantel (PZQ) is the only drug that is being used, since an effective vaccine 
is lacking. PZQ has high efficacy, tolerability, very few side effects, and a competitive cost. However, 
the occurence of PZQ resistance in patients and in the laboratory is increasing, so new 
schistosomicidal drugs are required (Neves et al. 2015). 
Praziquantel is a broad-spectrum anthelmintic developed in the 1970s and recommended by WHO 
(2006) for the treatment of schistosomiasis, that has been used for decades worldwide, mainly in 
endemic areas. Praziquantel has poor water solubility and resistance for the treatment of Schistosoma 
mansoni and S. japonicum (Wang et al., 2012). In addition, the treatment of infections caused by S. 
haematobium with praziquantel failed. Thus, different strategies against worms and eggs of 
Schistosoma spp. using nanotechnology have been examined to improve drug effectiveness. 
Liposomes containing anthelmintic have been used against S. mansoni, and their antiparasitic activities 
have been demonstrated in some studies. Some time ago, Frezard and Melo (1997) encapsulated 
oxamniquine, which is an anthelmintic, and these liposomes were effective against S. mansoni in a 
murine model when applied 3 days after infection. Liposome-entrapped oxamniquine reduced the 
number of parasites by 97% when injected subcutaneously one day before the infection, displaying 
excellent therapeutic efficacy. 
Liposomes with tartar emetic showed reduction of antimony toxicity and effective delivery in a 
murine model. Tartar emetic was entrapped in pegylated liposomes (11 mg Sb/kg intraperitoneally) 
and resulted in a 55% reduction in worm burden compared to the control group. However, the same 
liposomes with tartar emetic at a higher dose (27 mg Sb/kg) given subcutaneously and 
intraperitoneally reduced worms by 67% to 82% (Melo et al., 2003). 
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Liposomal praziquantel decreased the amount of schistosome eggs and worms in preclinical assays 
(Mourao et al., 2005; Freeza et al., 2013). Freeza et al. (2013) treated mice orally with praziquantel-
containing liposomes and only praziquantel 30 and 45 days following infection with S. mansoni BH 
strain. Liposomal praziquantel at 300 mg/kg resulted in a 68.8% decrease in the number of worms, 
79% in the number of eggs in intestine, and 98.4% in the number of hepatic granulomas compared to 
the controls. Yang et al. (2009) incorporated praziquantel into solid lipid nanoparticles and showed 
that noralpraziquantel bioavailability in rats increased significantly compared to free prazinquantel, 
suggesting the use of these nanoparticles as drug carriers. Similar results on oral bioavailability were 
observed in a study targeting the intestinal lymphatic system (Mishra et al. 2014). Souza et al. (2014) 
showed that solid lipid nanoparticles containing prazinquantel decreased toxicity in HepG2 cells when 
compared to free prazinquantel. 
Cationic nanoemulsions containing the schistosomicidal agent 2-(butylamino)-1-phenyl-1-
ethanethiosulfuric acid (BphEA) showed in vitro activity, indicating that cationic nanoemulsions can 
be used as delivery drugs against S. mansoni. BphEA has low water solubitity, hampering the 
application of this compound. These formulations have anionic and cationic interfacial charges with a 
droplet size ranging between 200 nm and 252 nm (zeta potential of 25.7 ± 3.9 mV). In this study, the 
schistosomicidal activity of cationic nanoemulsions was higher compared to that of free BphEA, 
indicating that a delivery system with this nanoemulsion could be interesting in the control of S. 
mansoni (Araujo et al., 2007). 
Vaccine candidates in nanoparticles have been studied in some neglected diseases. Fuaad et al. 
(2013, 2015) developed a vaccine candidate containing cathepsin D-derived epitope and a lipid core 
peptide system against schistosomes, which induced high levels of IgG without adjuvant, suggesting 
the use of nanoparticles as an immunogenic vaccine. This study also suggested the combined use of 
drug and vaccination with synergistic application as an interesting alternative to the conventional 
treatment of schistosomiasis. 
Polymeric nanoparticles such as poly(d,l-lactide-co-glycolide) acid (PLGA) and poly 
(methylmethacrylate) (PMMA) containing prazinquantel have been prepared and described as 
promising drug carriers. The drug encapsulation in polymeric nanoparticles increases water solubility 
and chemical stability (Mainardes and Evangelista, 2005; Fonseca et al., 2013ab). Mainardes et al. 
(2006) showed that PLGA nanoparticles with praziquantel had a more localized effect on intestinal 
membranes for a prolonged period of time. These physicochemical characteristics of polymeric 
nanoparticles lead to the control and gradual delivery of drugs. 
Another strategy for controlling schistosomiasis is by combating the mollusk vector Biomphalaria 
glabrata through the use of metal nanoparticles. Silver nanoparticles have been studied as a 
molluscicidal with low toxicity to other aquatic organisms (Yang et al., 2011; Guang et al., 2013). 
Thus, in controlling schistosomiasis, nanotechnology has been often reported as a great potential 
alternative for the treatment of the disease by improving the efficacy of drugs. 
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3.4. Trypasomiasis 
Human African trypanosomiasis (HAT) is caused by infection by Trypanosoma brucei gambiense 
or T. b. rhodesiense and transmitted to humans via the tsetse fly. In 1995, around 70 million people 
worldwide were under the possibilty of infection and currently around 20,000 people in Africa are 
infected with HAT (Sutherland et al., 2015; Nagle et al., 2014).  
Chagas‟ disease, or American trypanosomiasis, is caused by Trypanosoma cruzi and occurs in 21 
Latin American countries. Chagas‟ disease is endemic and primarily a vector disease affecting 
working people, on whom it has a strong economic impact. Approximately 10 million people are 
infected, and in endemic countries more than 25 million people are probably at risk. The heart is the 
most commonly compromised organ; symptoms include arrhythmias, cardiomyopathy, and 
thromboembolism. Death usually occurs from heart failure (Rodrigues-Morales et al., 2015) 
The drug pipelines for both diseases are minute: very few compounds are being developed, and 
drug discovery efforts are extremely limited. In clinical trials for HAT there are only two compounds 
(nifurtimox, SCYX-7158) indicating the need for enriching the pipeline with novel chemical entities 
of critical importance (Nagle et al., 2014). 
Benznidazole and nifurtimox are the only drugs with efficacy against Chagas‟ disease in human 
trials, and benznidazole is better tolerated and favored as the first-line treatment for Chagas‟ disease. 
Benznidazole is still used in Brazil (Pereira and Navarro, 2013). However, some patients tolerate 
nifurtimox better than benznidazole. Nevertheless, limited human data, supported by animal model 
data, suggest that T. cruzi strains may vary with respect to drug susceptibility (Bern, 2015). 
Nifurtimox and benznidazole (BNZ) are currently available drugs for the treatment of 
trypanosomiasis. Nevertheless, classical liposome encapsulation failed to improve the in vivo efficacy 
of nifurtimox and BNZ (Lamas et al., 2006). However, endovenous administration of liposomal 
etanidazole (ETZ) caused a substantial decrease in parasitemia levels of T. cruzi-infected mice. In fact, 
there is urgent ongoing research on new nanomedicines and nanostructured materials against 
trypanosomiasis (Salomon, 2011). 
It is known that amphotericin B binds to sterols of eukaryotic cell membranes, producing 
alterations in their permeability and also cell death. Its encapsulation in a liposomal formulation 
minimized the toxic side effects of this active compound. Several studies have demonstrated its in 
vitro trypanocidal activity (Haido and Barreto-Bergter, 1989; Castro et al., 1993), and a few reports 
reported the in vivo effect of amphotericin B formulations in mice infected with T. cruzi. Cencig et al. 
(2011) investigated the action of AmBisome (amphotericin B liposome) treatment, injected in six 
intraperitoneal applications at different times during acute and/or chronic phases of T. cruzi infection 
in mice, studying survival rates and parasitic loads in many tissues. These authors concluded that 
AmBisome therapy failed to completely cure mice infected with T. cruzi. However, it prevented 
mortality and effectively decreased parasitic loads in most tissues (i.e., liver, heart, spleen, adipose 
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tissues, muscle, and blood). Earlier administration of AmBisome (one day after parasite inoculation) 
produced a better response in diminishing parasite loads in the liver and spleen, where repeated 
treatment in the chronic phase reduced parasite load in the liver and heart. Therefore, this beneficial 
effect of AmBisome, observed with administration over a short time, should promote strategies for 
using nanoencapsulated amphotericin B in combination with other drugs (e.g., BZN) for a shorter 
recovery from T. cruzi infection (Cencig et al., 2011). 
SLNs are candidates in the treatment of neglected diseases, including trypanosomiasis (Olbrich et 
al., 2002). SLNs offer many advantages: they are biocompatible, solid at 25oC and body temperature 
(~37oC), protect the active compound against degradation, provide prolonged drug release and can be 
manufactured at large scale. Accordingly, Carneiro et al. (2014) reported in vitro and in vivo 
trypanocidal activity of 5-hydroxy-3-methyl-5-phenyl-pyrazoline-1-(S-benzyl dithiocarbazate) 
(H2bdtc) encapsulated in SLNs. H2bdtc is a potential drug lead to develop new agents against the 
trypomastigote form of Tulahuen strains of T. cruzi (Maia et al., 2010). Encapsulation did not change 
the in vitro activity of H2bdtc as a trypanosidal, which was more effective than BNZ. Indeed, 
treatment of mice with H2bdtc-SLN exhibited very promising results: (a) effective parasitemia 
reduction in mice at a concentration 100 times lower than that currently employed for BNZ clinical 
application; (b) decreased inflammation and lesions of heart and liver; and (c) overall survival of mice 
infected with T. cruzi (Carneiro et al., 2014).  
Allopurinol, violacein, grandisin, bis-triazole DO870, and megazol encapsulated in various 
biodegradable polymeric nanoparticles have shown interesting in vitro trypanocidal activity 
(Gonzalez-Martin et al., 2000; Durán et al., 2001; Molina et al., 2001; Stecanella et al., 2013; Lima 
and Albuquerque, 2012). Nanoemulsions of essential oils of andiroba (Carapa guaianensis) and 
aroeira (Schinus molle) were highly effective against T. evansi in vitro (Baldissera et al., 2013). 
Adeyemi and Whiteley (2014) performed a thermodynamic and spectrofluorimetric study on the 
interaction of metal nanoparticles (i.e., gold and silver) with arginine kinase (AK). Silver and gold 
nanoparticles bind tightly to the arginine substrate through a sulfur atom of a cysteine residue 
(Cys271). This interaction controls the electrophilic and nucleophilic profile of the substrate arginine 
guanidinium group, absolutely important for enzyme phosphoryl group transfer from ATP. This 
phosphotransferase is absent in humans, and the substrates that selectively inhibit AK are needed and 
should become candidates for trypanocidal drug studies (Miranda et al., 2006). However, all these 
reported studies need support from in vivo studies to validate the success of the proposed nanosystems. 
Besides, the scene could be different in vivo, since the nanomaterials used did not show any surface 
specific modification (e.g., biofunctionalization), which leads to their rapid clearance by macrophages, 
resulting in impaired trypanosomiasis treatment (Date et al., 2007; Kroubi et al., 2015). Moreover, in 
an in vivo study with mice infected with T. cruzi, it was demonstrated that bis-triazole DO870 
encapsulated in polyethyleneglycol-polylactide nanospheres affected a significant cure in these 
animals (Urbina, 2001; Molina et al., 2001).  
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Biofunctionalization consists of the surface chemical modification of nanocarriers with strategic 
biomolecules (e.g., folic acid, RGD peptide, sugars, proteins, antibodies, etc.) to achieve specific cell 
surface molecular interaction. This approach has been effective for targeted in vivo drug delivery with 
antitumor properties (Shao et al., 2015). Exploring the biofunctionalization approach, Arias et al. 
(2015) developed a new drug delivery system (polyvalent) for the treatment of African 
trypanosomiasis based on polymeric nanoparticles (PLGA) combined with nanobodies (single-domain 
antibody fragment obtained from functional heavy-chain antibodies of camelids) that on the parasite 
surface recognizes conserved cryptic epitopes. Pentamidine nanoparticles (first-line drug) were loaded 
for T. b. gambiense acute infection treatment. The IC50 value was 7-fold lower for the nanoparticles 
than for the free drug. Moreover, in vivo therapy in mice with African trypanosomiasis demonstrated 
that nanoparticles cured all infected mice at a 10-fold lower dose than the minimal fully curative dose 
of free pentamidine. In summary, this study demonstrated that the trypanosome surface chemistry is an 
important therapeutic target. Considering that the polyvalent drug delivery system was prepared using 
only components approved for their use in humans, including nanobodies, it is a promising 
nanosystem for practical uses in the treatment of human African trypanosomiasis (Arias et al., 2015). 
In another investigation, the trypanocidal drug pentamidine was also encapsulated in chitosan 
nanoparticles coated with nanobodies that specially reach the surface antigen of African 
trypanosomes. This chitosan-based nanosystem was effective in diminishing the minimal effective 
therapeutic dose of pentamidine in vivo, increasing its efficacy, significantly diminishing toxicity and 
overcoming drug resistance mechanisms (Unciti-Broceta et al., 2015). 
 
3.5. Leprosy 
Leprosy is still an important global health problem, since around 220,000 new cases are diagnosed 
annually. In Australia, the disease continues to be reported with an average of 10 new diagnoses 
annually, predominately in migrants from endemic areas, or from indigenous communities. 
Mycobacterium leprae infects the skin and peripheral nerves causing a chronic inflammation and 
neuropathy in a very slow-growing infection with an average of 12 years (Turner et al., 2015).  
Many different agents such as fluroquinolones, macrolides and minocycline have been tried in 
various formulations and different periods. Selective cytokine inhibitors, thalidomine analogues, and 
pentoxufylline have proved effective in controlling type-2 reaction in leprosy patients. However, new 
drugs are desirable for leprosy medical treatment (Prasad and Kaviarasan, 2010). 
In the case of paucibacillary (PB or tuberculoid) cases, treatment with dapsone (daily) and 
rifampicin (monthly) is recommended for six months. However, for multibacillary (MB or 
lepromatous) cases, treatment with daily dapsone and clofazimine along with monthly rifampicin for 
twelve months is suggested (Susuki et al, 2012).  
Multidrug therapy (MDT) is still highly effective, because of patients are not infectious after doses 
applied monthly. This procedure is safe and easy to use under any conditions due to the ease of 
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calendar blister packs, regression rates are low, and no resistance to the combined drugs has been 
observed (WHO, 2015a). 
Leprosy is a curable disease caused by the Mycobacterium leprae with well-defined etiology, but 
lacks better diagnostic tools and therapeutic strategies. There is no specific vaccine against M. leprae, 
and it is still a great challenge for research development. In this sense, nanobiotechnology is a 
promising strategy during the fabrication of selective biosensors and better drug delivery systems 
against this neglected disease (Goulart and Goulart, 2008). However, there are currently scarce reports 
in the literature involving the use of nanosystems for leprosy treatment. Liposomes containing 
clofazimine, an antibacterial agent active against M. leprae, was effective in reducing the time needed 
for leprosy treatment. In this case, liposomal formulation gel was tested on human cadaver skin 
demonstrated that liposomes not only prolong the drug release but also promote drug retention on the 
skin and reduce the healing time of external lesions (Patel et al., 1999ab). Liposomes were also 
effective in delivering antigens (i.e., murabutide and Trat peptide) against peripheral blood 
mononuclear cells derived from leprosy patients (Chattree et al., 2007). Besides, it was demonstrated 
that the expression of apoptotic markers (i.e., CD95 and CD95L) in T cells of leprosy patients 
increased after 5 days of M. leprae antigen stimulation. However, the percentage of expression of 
these apoptotic markers decreased significantly when the liposomal formulation was used. These 
results open the possibility of liposome application for the development of vaccines against M. leprae 
by activating the Th1 mediated immune response (Bisht et al., 2005).  
The therapeutic potential of leprosy drugs is greatly limited due to their insolubility in water. 
Schwinté et al. (2003) demonstrated that the solubility of clofazimine can be improved by a factor of 
30- to 50-fold after inclusion in cyclodextrin. Since 1943, dapsone (4,4'-diaminodiphenylsulfone) has 
been the drug of choice in the treatment of leprosy because it has bacteriostatic action against M. 
leprae. Despite its obvious therapeutic efficacy, the clinical use of dapsone is limited due to its low 
solubility in water (Santos et al., 2012). Moreover, it was recently demonstrated that it is possible to 
incorporate dapsone into nanoemulsion systems (from 6.0 to 12.0 nm) containing than can be used for 
topical and oral administration in humans. These nanoemulsions containing dapsone were prepared 
using isopropyl myristate, N-methyl-pyrolidone, propyleneglycol, Tween® 80 or Span®, and in vitro 
kinetics studies indicated the effective permeation of dapsone in porcine epidermis and Caco-2 human 
intestinal cell models (Borges et al., 2013, Monteiro et al., 2012).  
Recently, a rapid and low-cost assay used for screening the toxicity of nanoparticles (i.e., Ag, Cu(II), 
and ZnO) against pathogenic mycobacteria was reported (Donnellan et al., 2016). Fluorescence was 
used to monitor mycobacterial growth using nanoparticle concentrations in the range of 6.25 µg/mL to 
100 µg/mL for 7 days. The toxicity of NPs was ranked according to their specific composition in the 
following order: Ag> Cu(II)> ZnO. This new proposed bioassay is an interesting methodology to 
screen nanopharmaceuticals for leprosy treatment. 
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3.6. Tuberculosis 
In 2014, it was estimated that there were 9 million new tuberculosis (TB) cases in the world and 
around half a million of them were cuased by multidrug-resistant (MDR) mycobacterium tuberculosis 
strains (WHO, 2014). MDR-TB has in vitro resistance to isoniazid and rifampicin, while extensively 
drug-resistant (XDR)-TB is resistant to fluoroquinolone and one injectable second-line anti-TB drug, 
and to isoniazid and rifampicin (D´Ambrosio et al. 2015; Yuen et al., 2015). The evolution of anti-TB 
drugs is depicted in Figure 1. 
TB is still considered a severe disease, with 1.3 million TB deaths (including TB deaths in HIV-
positive individuals) being reported in 2012. TB is the major killer among adults in the economically 
productive age groups and people living with HIV. However, those cured from TB can exhibit 
sequelae that can substantially modify the government‟s agenda implemented since the early 1990´s, 
(Glaziou et al. 2015). Data showed that chemotherapy is one of the most cost-effective health-care 
interventions. The enormeous impact of the HIV epidemic on TB in Africa and the concern about the 
growth of MDR-TB has stressed the need to enhance TB prevention and control (Glaziou et al., 2015). 
Tuberculosis is an old complex contagious and chronic microbial infection widespread in human 
civilization since ancient times and first identified by Robert Koch on March 24, 1882. The etiological 
agents are the slow-growing actinomycetes Mycobacterium spp., particularly M. tuberculosis and M. 
bovis. In 1993, WHO declared global public health emergency for TB; later in 2006, it launched the 
Stop TB strategy linked to the Millennium Development Goal with the aim of reversing the trend by 
2015 (Zumla et al., 2013). TB is generally caused by the invasion of the alveolar macrophages of the 
lungs but also other organs in humans by the Gram-(+) bacteria Mycobacterium tuberculosis (Mtb). In 
2014, the global count for TB was estimated at 9 million and 1.5 million human new infections and 
deaths, respectively, and it is considered by the WHO as one of the most lethal diseases. Particularly, 
MDR-TB was detected in about a half million people (WHO, 2014; Uplekar et al., 2015). In addition, 
TB re-emergency is complex because it is sometimes associated with other pathologies such as HIV in 
asymptomatic patients (Gandhi et al., 2010; Lalloo and Ambaram, 2010). TB is considered a top killer 
among adult people during the most economically productive ages, also in people having HIV, and at 
present the quality of life of TB-cured patients is substantially reduced. This evidence has made TB a 
priority in the world health agenda since the 90`s (Glaziou et al. 2015). 
Anti-TB drugs were developed in many laboratories, distributed and widely administered after the 
Second World War. However, no novel anti-TB drugs have appeared in the market since 1952, (Lalloo 
and Ambaram, 2010; Sosnik et al., 2010) (Figure 2). The most effective anti-TB drugs available in the 
market are rifampicin, pyrazinamide, isoniazid, and ethionamide (Mehanna et al., 2014; Kaur and 
Singh, 2014). However, two major problems associated with the drug still prevail, namely, reaching 
high drug concentration inside the lung macrophages and the MDR and extensively drug resistant 
(XDR) M. tuberculosis, which are making the therapy ineffective (Pandey and Khuller, 2005). In TB, 
in vitro microbial resistance to at least isoniazid and rifampicin is considered MDR, while extensively 
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drug-resistant TB occurs when the microorganism is resistant to at least one fluoroquinolone and one 
injectable second-line anti-TB drug plus isoniazid and rifampicin (D´Ambrosio et al. 2015; Yuen et 
al., 2015). 
The following strategies were established to develop novel anti-TB weapons: 
First, the priority was focused on the synthesis and discovery of new drug candidates for patients 
associated with complex pathologies such as TB coinfection in HIV positive patients, which are now 
at different levels of clinical trials (Table 1).  
The second strategy was based on the new discoveries in physiology combined with molecular 
biology, which are provide strong candidates such as small interfering RNAs (siRNAs) for the 
treatment of different resilient pathologies including TB (Merkel et al., 2014). The fundamentals of the 
siRNAs mechanism are based on the inhibition of posttranscriptional gene expression in the target 
cells by RNA interference (RNAi), activating the degradation of mRNA and consequently, cell 
apoptosis. The mechanism of RNAi starts by delivering small interfering RNA/RNAs, usually of 21-
26 synthetic oligonucleotides length, inside the microbial cells, or alternatively long double-stranded 
RNAs, and also plasmid DNA containing short hairpin RNAs that are processed by Dicer (nuclease) 
biocatalyst into siRNA. In vitro and in vivo experiments in mice using siRNA anti-TB showed 
promising therapeutic results (Dhiman et al., 2008; Rosas-Taraco et al., 2011). The in vitro studies 
using siRNA performed in human monocyte-derived macrophages infected with two different strains 
of M. tuberculosis targeted the expression of the antiapoptotic bfl-1/A1protein. The inhibition of bfl-
1/A1protein synthesis in both Mtb strains by the siRNA induces the apoptotic cascade in infected 
macrophages, without any detectable effect on uninfected cells (Dhiman et al., 2008). Alternatively, 
siRNA molecules were used in vivo to enhance the immune response to chronic infection produced by 
Mtb in mice. The main idea was to activate the expression of the TGFb1 protein by inhibiting the 
immunosuppressive cytokine TGFb1 using siRNA, and consequently Th1 is enhanced and 
macrophage activation occurs concomitantly with the immune response in mice. Another advantage of 
this strategy is the increased expression of unspecific antimicrobial molecules such as NO and iNOS 
by the depletion of TGFb1 expression, which cause lethal effects on microbial invaders (Rosas-Taraco 
et al., 2011). Besides the promising siRNA strategies on anti-TB therapies, the main challenge remains 
in the selection of proper RNAi and the strategies for molecular delivery to the target cells (Lam et al. 
2012, Merkel et al., 2014). 
The third alternative of anti-TB therapies is based on the administration of drug contained in specific 
nanodevices, which target infected cells only, using proper amount of the drug under the therapeutic 
windows, lowering drug concentration in the patient, reducing undesirable side effects, and avoiding 
Mtb resistance mechanisms. However, the task is complex since anti-TB therapies usually require 
extended treatment because of low antibiotic permeability through the membranes, antibiotic 
instability under physiological conditions, and limited drug administration due to its high toxicity. 
Strategies of molecular delivery, based on passive and active mechanisms developed in the carriers 
26 
 
using nanontechnological approaches, are now in progress. There are many nanodevices reported in 
the literature but they can mainly be grouped into the following: 
- Micro- and nanoparticles synthesized using natural and synthetic polymers such as polylactic 
acid, acrylate derivatives, collagen, alginic acid, and mixtures of them.  
- Lipidic nanostructures such as archeosomes, solid lipid nanoparticles, nanostructured particles, 
liposomes, and micelles. The systems are configured by combining several types of lipids such as 
stearic, oleic, linoleic acids, phosphatidylcholine-cholesterol/ phosphatidylcholine and 
cholesterol, or synthetic molecules such as Spams (®), and non-lipidic molecules (surfactants, 
proteins, etc.).  
- Hybrid systems developed using coacervates o molecular solutions, such as caprolactone-co-
glycolide, chitosan-PLA, wheat germ agglutinin, and PGLA. 
Drug delivery nanodevices were recently reviewed (Kaur and Singh, 2014; Mehanna et al., 
2014). 
 
3.7. Filiarasis and onchocerciasis 
Filariasis is caused by parasitic worms called filariae. Filariae are microscopic roundworms that 
dwell in the blood and tissues of humans. The most important filarial diseases for humans are 
lymphatic filariases, in which the adult worms are found in the lymphatic system. Lymphatic / 
Lymphatic filariasis is sometimes also referred to  as elephantiasis (Chandy et al., 2011; Yadav and 
Srivastava, 2014). 
Ivermectin and suramin are extremely potent semisynthetic derivatives of the antinematodal 
principle obtained from Streptomyces avermitilis. In 2010, Turner and coworkers proved the 
microfilaricidal activity of doxycycline against Onchocerca volvulus (O.volvulus) in an area of Loa 
loa co-endemicity, which is one of the filaria nematodes (Turner et al., 2010). Mebendazole and 
flubendazole irreversibly block the uptake of exogenous glucose by nematodes, producing glycogen 
depletion and low generation of ATP required for survival. Due to these effects, the parasites die, or 
are slowly immobilized and gradually eliminated from the gut. Human blood levels are not affected. 
Diethylcarbmazine (DEC) has a highly selective effect on the microfilariae. Concomitant 
administration of corticosteroids with DEC is now considered the most appropiatre treatment in order 
to minimize the allergic manifestations secondary to the disintegration of microfilariae, particularly in 
O. volvulus and L. loa infections.  
Onchocerciasis is caused by infection with the filarial nematode Onchocerca volvulus and can 
result in eye or skin lesions. The parasite is transmitted to humans by black flies of the genus 
Simulium. In 2007, WHO (2015b) estimated 37 million persons were infected with onchocerciasisin in 
endemic countries (30 in Africa, six in the Americas, and one in the Arabian Peninsula). The strategy 
of the Onchocerciasis Elimination Program of the Americas (OEPA) is to support national programs in 
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the six endemic countries to provide twice-yearly mass drug administration (MDA) of ivermectin to 
≥85% of the eligible population at risk (Cruz-Ortiz et al., 2012). 
As mentioned before, filiarasis is a tropical disease caused by filarial worms, Wuchereria bancrofti, 
Brugia malayi or B. timori.The infection can be treated with drugs such as diethyl-carbamazine citrate 
(DEC), albendazole, tetracycline, ivermectin, and suramin. About 98% of the infected populations are 
living in African and South-East Asia regions. Onchocerciasis, commonly known as “river blindness”, 
is caused by the parasitic worm Onchocerca volvulus. It is transmitted to humans through exposure to 
repeated bites of infected blackflies of the genus Similium. 
WHO states that currently, more than 99% of infected people live in African countries; the disease 
also exists in some foci in Latin America and Yemen (WHO, 2015b). Today, it is treated with 
invermectin as the main strategy to eliminate onchocerciasis in Africa (Hoerauf, 2008).  
In some cases of fungal and parasitic skin infections, nanotechnology appears to iniciate an attempt to 
improve existing treatments (Leslie et al., 1993). Since the 1990´s, many nanostructures have been 
investigated to improve the treatment of neglected diseases. 
DEC encapsulated in liposomal forms was effective in the elimination of filarial parasite infected by 
Brugia malayi from systemic circulation up to 60 days postinfection in animals (Owais et al. 2003). In 
addition, the coadministration of liposomal formulation of DEC with tuftsin (immunomodulator), 
which is a suppressor of the microfilarial stage of the parasite after 90 days posttreatment, was also 
effective against the adult parasite. 
To treat infection by Wolbachia bacteria symbiont to filarial parasite, Bajpai et al. (2005) reported the 
use of tetracycline in a liposome formulation. The liposome loaded with tetracycline was found to be 
more effective when compared to the free form of the drug, eliminating tetracycline toxicity. The 
relevance of using this type of liposome formulation was demonstrated in the response, as compared 
with free forms of treatment of human lymphatic filariid Brugia malayi infection in rodent host 
Mastomys coucha. The liposomal formulation increased the time of the drug release up to 48 h, which 
decrease A. aegypti the number of administrations and lowered the possibility of toxic effects. When it 
was combined with liposome-encapsulated antibiotics, it enhanced microfiliaricidal activity, but was 
not so efficient in adulticidal activity (Dangi et al., 2010). 
To improve targeting to lymphatics and to increase the retention time of DEC, Kartick (2014) 
encapsulated this drug in SLNs. All the parameters studied improved and their entrapment efficiencies 
were significant (~70%). DEC release time from SLNs was around 150 min. A study in Sprague 
Dawley rats showed an approximate 5-fold increase in the amount of DEC that reached lymphatics in 
the case of SLN encapsulation, compared with the free form of DEC. This high DEC concentration led 
to the elimination of microfilariae from the lymphatics. 
To extend the release of drugs Moghimi et al. (1994) formulated a polystyrene system as nanospheres 
administered by subcutaneous injection in Wistar female rats to verify drainage and passageway 
across the tissue lymph interface in dermal lymphatic capillaries in the rat footpads. The authors 
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observed a rapid drainage of the polymer-coated nanospheres from interdermal tissue when compared 
to uncoated nanospheres, minimized interactions between macrospheres (when coated, their size 
increases) and amorphous ground substances, faciliting the movement of nanospheres from the 
interstitium towards the lymphatic system.  
Another study developed nanosphere for lymph node targeting qualities by Hawley et al. (1997) 
developed nanospheres with good lymph node targeting characteristics for subcutaneous injection in 
rats, using poly(lactide)-poly(ethylene glycol) (PLA:PEG), polystyrene (PS) and poly(lactide-co-
glycolide) (PLGA) nanospheres and copolymers. The surface-modified nanospheres were very useful 
for targeting the treatments of lymph nodes. 
Rao et al. (2010) studied nanoparticles prepared by nanoprecipitacion. The nanoparticles formed by 
conjugation were PLGA-PMA (1-pyrenemethylamine): PLA-PEG (PP) and PLGA-PMA:PLGA-
COOH (PC) in different proprortions and sizes. All rats received nanoparticles containing polymerin 
differents lymph regions (nodes of interest). Nanoparticles were administered by subcutaneous 
injection in rats and they were monitored and evaluated by various techniques (in vivo study). The in 
vitro study was just to evaluate the degradation of nanoparticles. Lymphatic absorption and node 
retention of PP nanoparticles appeared to be inversely related to size and hydrophobicity. On the 
contrary, these processes with PC nanoparticles were directly proportional to the anionic charge on the 
particles. The best PP particle size for in vivo lymphatic uptake and retention in a rat model was  50 
nm. PPs were adequate for sustained release and delivery into the lymphatics for prevention and/or 
treatment of oligometastases. 
Ali et al. (2013) encapsulated ivermectin at a 3:1 ratio of poly (lactic-co-glycolic acid) (PLGA) 
nanoparticles with polyvinylalcohol (PVA) (nano-IVM) as surfactant by nanoprecipitacion or 
emulsion-solvent evaporation methods, to test against human lymphatic filariid Brugia malayi in 
rodent host Mastomys coucha. Finally in vivo studies showed that a combination of entrapped IVM 
(nano-IVM) with DEC had an enhanced microfilaricidal effectiveness and slightly better 
macrofilaricidal effectiveness than any of the single formulations or free drug combinations. 
Subcutaneously administered ultrafine PLGA nanoparticles containing doxycycline hydrochloride 
against lymphatic filarial parasites have been recently reported (Singh et al., 2016). 
The biodegradable polyanhydride nanoparticle-based platform for the codelivery of the antibiotic 
doxycycline with the antiparasitic drug, ivermectin, to reduce microfilarial burden and rapidly kill 
adult worms was recently published (Binnebose et al., 2015). 
A study was carried out to compare the administration route and the enhancement of uptake in the 
lymphatic system using  emulsion nanoparticles of standard DEC drug  for filariasis (Karajgi and 
Vyas, 1994). It was found that intraperitoneal injection (ip) was better than intravenose administration 
(iv) in which lymphatic uptake was not observed. The authors suggested that a nanoparticle-in-oil 
emulsion system exhibited excellent potential as a lymphotropic carrier system. 
29 
 
Ravichandran (2010) tested a new nanosuspension tablet (nanonization by high-pressure 
homogenization) of albendazol in rats, which showed a bioavailability 2 to 3 times larger than that of 
the existing drugs in the market. 
To evaluate the larvicidal effectivity, a study against filariasis vector, Culex quinquefasciatus (C. 
quinquefasciatus), was conducted using silver nanoparticles synthesized by Eclipta porstata extract 
(Rajakumar and Rahumam, 2011). The results showed that biogenic silver nanoparticles presented a 
good activity against larvae of C. quinquefasciatus, (LC50= 4.56 mg/L). 
Dhanasekaran and Thangaraj (2013) obtained larvicidal results with biogenic nanoparticles (from 
extract of Agaricus bisporus) against the mosquito vector of lymphatic filariasis (Culex sp.). The 
larvacidal activities were analyzed by standart procedures recommended by WHO. Every 3 h,  for 24 
h, mortality was assessed to determine acute toxicity. Particularly, 5.0 mg/L biogenic nanoparticles 
made of Agaricus bisporus kill 100% of Culex larvae. Very recently, Murugan et al. (2016d), 
Govindarajan et al. (2016) and Adesuji et al. (2016) showed the effect of biogenic silver nanoparticles 
on the filiarasis vector Culex quinquefascius, among othersh. Unfortunately, in all these cases, the 
silver chloride nanoparticles appeared complexed with silver nanoparticles, and not only silver 
nanoparticles were acting on the vectors as reported. 
 
3.8. Toxoplasmosis 
Toxoplasmosis infection by the protozoan parasite Toxoplasma gondii has a worldwide 
distribution. This parasite belongs to the coccidian subclass, phylum Apicomplexa, and the three 
parasitic stages (tachyzoite, cyst, and oocyst) have been completely characterized. Toxoplasmosis 
encephalitis (TE) in Toxoplasma-seropositive AIDS patients must be managed with trimethoprim-
sulfamethoxazole (TMP-SMX) prophylaxis. If patients cannot tolerate TMP-SMX, they must use 
dapsone-pyrimethamine plus folinic acid. A twice weekly treatment with pyrimethamine-sulfadoxine 
has proved to be effective, but skin toxicity limits its use. Atovaquone with or without pyrimethamine-
folinic acid has also been considered, since it is efficiently absorbed in the digestive tract. 
Toxoplasma-seronegative persons must be checked annually for IgG antibody to Toxoplasma to 
determine whether they have seroconverted with the risk of TE (Robert-Gangneux and Dardé, 2012). 
In the area of nanotechnology, many new drugs have been reported for therapeutic purposes of 
toxoplasmosis. The common treatment of toxoplasmosis usually reported by the Centers for Disease 
Control and Prevention (CDC, USA) is a combination of drugs such as pyrimethamine and 
sulfadiazine, plus folinic acid. 
In the 1990s, liposomal carriers were important to initiate a new form of combating the protozoans. 
Tachibana et al. (1990) used stearylamine-bearing liposomes (SA/PC) against Toxoplasma gondii (RH 
strain) in the tachyzoite phase, using in vivo and in vitro assays. They were injected in female mice to 
assess their toxicity. Each group received 1, 5 or 10 mg/mL of 30 mol% SA/PC-liposomes after T. 
gondii strain infection. They found that in vitro viable activity of SA/PC liposomes gradually dropped 
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with the decrease in liposome concentration. In vivo results showed that SA/PC-liposomes had 
preventive and curative effects. 
Another study involving liposomes and toxoplasmosis was conducted by Elsaid et al. (1999, 2001). 
They studied antigens incorporated in liposomes against T. gondii in mice. ELISA antibody level, after 
immunization, was higher in all mice immunized with T. gondii antigen, but the differences between 
groups were not statistically significant. However, immunization with purified 32-kDa antigen of 
tachyzoite (L/pTAg) or total tachyzoite and/or bradyzoite antigen encapsulated in liposomes enhanced 
protective immunity (humoral and cellular), probably contributing to the limitation of the systemic 
spread of T. gondii and reducing the vertical transmission of toxoplasmosis. 
Recently, El-Zawawy et al. (2015) tested the effectiveness of triclosan (TS) and triclosan-loaded 
liposomes (liposomal-TS) against a virulent strain of T. gondii in Swiss albino mice. The infection was 
intraperitoneal and the treatment was oral. After treatment, both TS and liposomes-TS induced 
significant reduction of parasite (tachyzoite) burden; however, the latter was more efficient. Other 
parameters such as mouse mortality and viability, morphology alteration and infectivity of tachyzoites 
from infected mice in comparison with noninfected mouse controls showed the same profile. The 
authors concluded that when TS was loaded in liposomal structures the release phase was longer, 
prolonging the TS action in peritoneal fluid and in the liver. 
As noted above, other authors decided to test a standard drug such as pyrimethamine (PYR) in the 
treatment of toxoplasmosis after modification using nanotechnology. Pissinate et al. (2014) compared 
SU-PYR (surfactant prepared) and PYR-loaded lipide-core nanocapsules (PYR-LNC), using poly (Ɛ-
caprolactone) (PCL), against T. gondii. They used LLC-MK2 (kidney, Rhesus monkey, Macaca 
mulata) strain in an in vitro assay. In vivo studies using peritoneal injections were carried out in mice. 
Comparative formulations were prepared just with LNC (lipid-core nanocapsules). Body weight gain 
was used as the parameter to confirm the toxicity of formulations after 10 days. The LLC-MK2 cells 
showed the same tolerance with PYR-LNC and PYR solution, but proliferation was affected with 
TC50 values of 6.0 μM for both formulations. After 8 days, the untreated mice and LNC group died. 
The group treated with PYR-LNC showed better results than that treated with SU-PYR. After 60 days, 
the mice treated with 10 mg SU-PYR (10%), 7.5 mg PYR-LNC (15%), and 10 mg PYR-LNC (30%) 
were alive.  
To improve the effect of atovaquone, which previously demonstrated good results in in vitro responses 
against T. gondii, Scholer et al. (2001) prepared atovaquone nanosuspension (ANS) for in vitro and in 
vivo assays. The in vitro test after 48 h of treatment showed a decrease in infection capacity of the 
parasite in the presence of both formulations (SLAs and drug-free), and growth was almost inhibited at 
concentrations above 1.0 μg/mL. With regard to cytotoxicity, viability was high (~80%) even up to 3.0 
μg/mL and remained stable from 1.0 μg/mL. All animals received sulfadiazine for 3 weeks and then 
started with the ANSs and free atovaquone. A survival rate of 88% was obtained during the treatment 
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with therapeutic effects (10 mg/kg body weight/day). These results indicated a good direction to the 
treatment against T. gondii. 
Rhodamine B-labeled polystyrene latex particles were coated with polybutyl cyanoacrylate under 
physical inclusion of two different new drugs against toxoplasmosis. Pentamidine-loaded as well as 
pentamidine-free core-shell model drug carriers were added to cultured human macrophages (J774-A1 
cells), infected by T. gondii, following an infection protocol. As the main result, the drug-free 
references in the two series of core-shell model drug carriers achieved ca. 85% of the observed 
maximum effectiveness of toxoplasmosis therapy. These data correlated well with an 
immunestimulating effect on the human macrophages, caused by the cell uptake of colloidal substrate, 
foreign to the body (Leyke et al., 2013). 
The data that unloaded pentamidine nanoparticles had the same effect as penramidine-loaded 
nanoparticles offer the opportunity to use the nanoparticles directly for treatment. Perhaps, part of the 
effect of atovaquone crystal nanoparticles in a Toxoplasma-mouse model should be attributed to the 
effect of nanoparticles (Scholer et al., 2001), rather than to the direct effect of the drug against the 
parasite. 
One of the clinical manifestations of infection caused by T. gondii is toxoplasmic encephalitis (TE). It 
could be lethal if the patient does not receive treatment. The most effective treatment causes 
hematological disturbances and allergic reactions. To eliminate these effects, atovaquone was prepared 
as nanoscale suspensions (ANSs) capped with poloxamer 188 (P188) and sodium dodecyl sulfate 
(SDS) (SDS-coated ANS) (Shubar et al., 2011). The authors compared ANSs to commercial 
atovaquone (Wellvone) in murine models. They observed an increase in oral bioavailability and 
decrease of inflammatory signs in the brain of animals treated with SDS-coated ANS. 
Gaafar et al. (2014) conducted a study involving two types of nanoparticle, silver nanoparticles (Ag 
NPs) and chitosan nanoparticles (CS NPs). After animal infections (male Swiss albino mice), three 
different treatments were tested (CS NPs, Ag NPs, and their combination) and compared with two 
controls (healthy animals and infected animals without treatment). Toxicity was determined by the 
concentration of Ag in different tissues (intestine, liver, kidney, brain, and lungs). A low parasite count 
resulted in the group that received CS NPs/Ag NPs (100 μg/mL/100 μg/mL) after 4 days of infection. 
The best result found was that the concentrations of Ag particles in the main tissues stayed within the 
safe range of 9 μg/g body weight, with the highest level being detected in the liver followed by 
intestine, kidney, lungs, and brain. 
 
3.9. Dengue virus and others viruses 
Dengue virus infection (DVI) causes different kinds of illness ranging from asymptomatic infection 
to a flu-like mild undifferentiated fever with high fever over the 40°C (Benelli and Mehlhorn, 2016; 
Durán et al., 2016a). Other diseases can mimic DVI, such as influenza, measles, typhoid, leptospirosis 
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or any nonspecific viral syndrome. A definitive diagnosis of DF therefore can only be made by 
specific laboratory test (Mungrue, 2014). 
DVI infection is the wildest mosquito borne infection affecting 2.5 billion people in tropical and 
subtropical regions of the world. DVI is a member of Flaviviridae family and is transmitted to humans 
by infected female Aedes genus, especially Aedes aegypti and/or Aedes albopictus (Beatty et al., 
2010). 
The only treatment against dengue is preventive and supportive care. Several research studies have 
been conducted to use siRNA against DVI, and many of them have provided results of effectively 
using siRNA against DVI replication (Idrees and Ashfag, 2013). Also, molecules such as iminosugars, 
such as deoxynojirimycin (DNJ) and its N-alkylated derivatives, demonstrate antiviral activity against 
DVI by targeting host cellular factors required for viral morphogenesis (Sayce et al., 2010). The 
flavonoids fisetin and quercetin and baicalein also exhibit anti-dengue virus activities (Zandi et al., 
2012). New approaches in DV and ZV treatments now focus on the use of nanoparticles combined 
with natural and more effective molecules as efficient antiviral systems (Duran et al., 2016). 
Current challenges in the treatment of Dengue and Zika viruses  focus on the development of 
effective antivirals based on nanoparticles (Durán et al., 2016a) (Figure 6). In addition, there are some 
discussions about the perspectives of nanodevices in other viral illnesses, especially in those which do 
not have an established cure or new alternatives in treatment are under exploration (HIV, HBV, etc.). 
During the last decades, eradication of virus infections has been a challenge in the medical field, since 
the problem is not only the spread of viruses but also their ability to evolve by mutations in the genetic 
material, which makes them a real nightmare in health.   
Particularly, the dengue virus possesses four distinct, but closely related, serotypes (named DEN-
1, DEN-2, DEN-3 and DEN-4), which makes targeting difficult. The virus attack may cause a 
spectrum of illnesses from the more moderate, such as the asymptomatic state or flu-like mild 
undifferentiated fever, to the more severe such as the famous dengue fever with hemorrhagic 
problems. If subsequent infections by other serotypes are produced, the risk of developing severe 
dengue increases (Mungrue, 2014). Currently, there are no approved vaccines or antiviral agents 
against the dengue virus, which opens a gate for the design of new strategies to effectively combat the 
infection, and nanotechnology appears as a new feasible alternative. A promising vaccine has been 
developed and tested, but only a partial and heterogeneous efficacy was found. In addition, it is 
suspected to be responsible for adverse side effects (López-Gatell et al., 2016). 
Nowadays, the only treatment against dengue is preventive and supportive care. For these reasons, the 
development of new rapid and specific diagnostic systems is a useful tool for prematurely detecting 
the infection at its initial stages. Some nanodiagnostic tools are based on nanomaterials such as 
liposomes, nanopores and nanowires, which are coupled with conventional methods such as 
fluorescence, potentiometry and voltammetry. Most of them include enzyme-linked immunosorbent 
assays and reverse transcriptase polymerase chain reaction.  Although these systems give rapid 
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diagnostics and use inexpensive materials, they are currently unavailable for practical use in clinical 
practice (Peh et al., 2010). An effective biosensor was developed by the use of an optical membrane-
based DNA/RNA hybridization system using liposome amplification, which allows the detection of 
generic and serotype-specific synthetic dengue genomic sequences (for serotypes 1−4) in blood 
samples of patients. The method uses a biotinylated DNA capture probe immobilized on a 
streptavidin-coated polyethersulfone membrane, in addition to a generic DNA reporter probe coupled 
to the outer surface of dye encapsulating liposomes. When the sample of amplified ARN passes 
through the capture zone of the membrane strip, the quantification of reporter probe-tagged liposomes 
is proportional to the number of RNA molecules present in the sample, and the signal is detected by 
electrochemiluminescence. While the nonspecific RNA molecule does not generate a signal, a generic 
sequence added to the dengue RNA during the amplification step  is hybridized and the signal is 
turned on.  This biosensor showed an excellent correlation in detection, is portable, inexpensive, and 
very easy to use (Baeumner et al., 2002).  
Another diagnostic approach proposes the use of a silicon nanowire (SiNW)-based sensor for the 
detection of products from DEN-2 genes after reverse-transcription-polymerase chain reaction (RT-
PCR) by the hybridization with a specific peptide nucleic acid (PNA) covalently attached onto the 
SiNW surface. The positive reaction was verified by measuring the change in resistance of the SiNW 
before and after hybridization (Zhang et al., 2010). 
In this scenario, research groups have proposed the green-synthesis of silver nanoparticles (AgNP) as 
novel and effective tools against the different dengue serotypes. The use of natural extracts of plants as 
reducing and stabilizing agents for nanoparticle preparation provides interesting properties.  
More recently, gold nanoparticles have been used for highly sensitive and rapid detection of dengue 
infection. In one study, a diagnostic device was developed for serum detection of antigens from a 
nonstructural protein (NS1) responsible for dengue virus pathogenicity by an immunoassay with 
nanogold particles conjugated to antibodies from NS1 (Hussain et al., 2014). Jahanshahi et al. (2014) 
developed a new method based on surface plasmon resonance (SPR) for detection of anti-dengue virus 
in human serum in less than 10 min. The DEN-1, DEN-2, DEN-3, and DEN-4 serotypes were 
immobilized onto the biochip surface that consists of a gold coating on glass accompanied by 
nanoparticles and the immobilized antigens. Another study proposed the detection of dengue-specific 
immunoglobulins (IgGs) in salivary fluids by stacking flow immunoassay, in which the liquid 
conjugate was composed of G protein conjugated to 40 nm gold nanoparticles. The importance of 
IgGs detection lies in distinguishing between primary and secondary dengue infection, since IgGs are 
only present in second episodes (Zhang et al., 2015).  
The presented nanodiagnostic systems provide an insight into the mechanisms and bases of detection 
and how to increase the sensitivity in the shortest time, which is feasibly extrapolable to detection of 
other viral pathologies.  
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Once viral infection is established, new alternatives in treatment are required and need to be explored. 
Several research studies have been conducted on the use of small interference RNA (siRNA) as a next 
generation in the treatment of dengue infection, since the siRNA could effectively inhibit the virus 
replication (Idrees and Ashfag, 2013).  
However, some studies showed that antivirals could be an interesting trend in the coming future. 
Iminosugars, such as deoxynojirimycin (DNJ) and its N-alkylated derivatives, have demonstrated 
antiviral activity against DVI by targeting host cellular factors required for viral morphogenesis 
(Sayce et al., 2010). Flavonoids such as fisetin, quercetin and baicalein also exhibited anti-dengue 
virus activities, particularly against DEN-2 serotype, by a mechanism that is probably related to 
inhibition of RNA polymerase (Zandi et al., 2011, 2012).  
Nevertheless, this kind of compound commonly showed a low bioavailability, especially for 
therapeutic uses, so several strategies to overcome this limitation are focused on the use of a wide 
diversity of nanocarriers including liposomes, solid lipid nanoparticles, nanoemulsions, nanocrystals 
or polymeric nanoparticles, among others (Teles et al., 2005). 
Liposomal formulations have shown interesting properties in terms of the effective dose of antiviral, 
decreasing the toxic concentrations and enhancing the retention time of the drug at blood circulation 
(due to PEGylation). Experiments in vivo with a lethal antibody-dependent enhancement mouse model 
of dengue pathogenesis demonstrated that delivery of iminosugars (all deoxynojirimycin derivatives) 
via polyunsaturated ER-targeting liposomes (PERLs) increases the survival rate and prevents the viral 
accumulation in organs and serum. In comparison with free administration of iminosugars, liposomes 
only need a 3-log10 less dose to achieve the survival of the animals. In addition, the formulation 
exhibited a greater in vitro potency against dengue virus by inhibiting both the number of infected 
cells and the release of infectious viral particles from primary human monocyte-derived macrophages 
(Miller et al., 2012).  
Alternatively, AgNP synthesized using the Moringa oleifera seed extracts showed in vitro antiviral 
activity against DEN-2 infecting Vero cells. Also, those nanoparticles were highly effective against 
the dengue vector A. aegypti (Sujitha et al., 2015). In a similar work, biosynthesized AgNPs using the 
aqueous extract of Bruguiera cylindrica leaves were tested against A. aegypti at low doses to reduce 
larval and pupal population of A. aegypti (Murugan et al., 2015). Also, the use of alga-mediated 
synthesis of metal nanoparticles becomes an interesting tool to fight the dengue virus and its vector A. 
aegypti, showing a reduced cytotoxicity in mammalian cells (Murugan et al., 2016). Other approaches 
suggested the use of carbohydrate polymers for the preparation of silver nanoparticles with bioactive 
properties similar to the commercially available AgNPs (Saha et al., 2016). However, despite the in 
vitro effectiveness of mosquitocidal nanoparticles prepared with natural products at laboratory scale, 
more studies are needed about their possible nontarget effects against mosquito's natural predators and 
other aquatic organisms (Benelli 2016). Regarding the Zika virus, eco-friendly silver nanoparticles 
were also employed. A low-cost technology based on extracts of Hugonia mystax showed toxic effects 
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against Anopheles stephensi, Aedes aegypti, and Culex quinquefasciatus larvae, while a reduced 
toxicity was observed for aquatic biocontrols of Gambusia affinis, Diplonychus indicus, and Anisops 
bouvieri (Govindarajan et al., 2016a). Similar recent studies have focused on the biofabrication of 
Quisqualis indica-AgNPs as an eco-friendly tool against Zika virus, malaria and filariasis vectors 
(Govindarajan et al., 2016b). Also, polydispersed silver nanocrystals using Malva sylvestris are an 
ecological alternative to kill the mosquito larvae (Govindarajan et al., 2016c).  
Interestingly, the extrapolation of the techniques to treat other related viruses was compared. The 
ability of PERLs to produce a cholesterol-lowering effect impacts positively on the inhibition of virus 
replication, and antiviral activities were observed not only for dengue virus, but also for hepatitis B 
virus (HBV), HCV, and HIV-1 (De Mareuil et al., 2002; Pollock et al., 2010). Clayton et al. (2009) 
designed pegylated liposomes with the surface covered by targeting ligands derived from the Fab‟ 
fragment of HIV-gp120-directed monoclonal antibody F105, and evaluated the encapsulation of a 
novel HIV-1 protease inhibitor. They demonstrated that immunoliposomes were effectively targeted 
and internalized into HIV-1-infected cells, delivering and accumulating the protease inhibitor into 
cytoplasm. These results highlight the potentiality of the liposomal carriers as vehicles for antivirals 
and the possibility to transport other cytotoxic drugs for a wide array of viruses. 
Other studies have considered the development of solid lipid nanoparticles and nanostructured lipidic 
carriers as possible matrices for the encapsulation of antivirals against dengue virus. Baicalein, a well-
known flavonoid with antiviral activity, was encapsulated in SLN at 60.73% by a solvent injection 
method and showed a controlled release profile (Liu et al., 2009). In a similar way, baicalein was 
incorporated into 100 nm tocol NLCs for intravenous administration, detecting higher plasmatic levels 
and a longer half-life than administration of free antiviral (Tsai et al., 2012). SLN also improved the 
poor orally availability of lopinavir (antiviral for HIV) by encapsulation in glyceryl behenate based 
SLN for delivery targeted to intestinal lymphatic vessels (Alex et al., 2011). 
The preparation of nanoemulsions is an attractive model to incorporate essential oils for the control of 
vector-borne diseases. Ghosh et al. (2013) proved that these formulations mixed with essential oils 
derived from plants have a dose and time dependence for killing the mosquito larva of Aedes aegypti. 
Another group found similar results with a nanoemulsion containing Rosmarinus officinalis essential 
oil (250 ppm concentration) and evaluated its larvicidal activity against A. aegypti larvae, observing 
mortality levels of 80 ±10%  and 90 ±10% after 24 h and 48 h, respectively (Duarte et al., 2015).  
Several polymers such as poly(lactide-co-glycolide) (PLGA), poly(D,L-lactic acid) (PLA), 
polyglycolide, polycaprolactone (PCL), poly(d,l-lactide), chitosan, and PLGA–polyethylene glycol 
(PEG) have been developed for passive and ligand-targeted delivery of therapeutic drugs (Prabhu et 
al., 2015; Jhaveri and Torchilin, 2015). In particular, it was observed that carriers for antiviral drugs 
exert the antiviral activity of the encapsulated molecules, indicating that direct interaction between the 
nanoparticles and the virus may inhibit the viral attachment to cells (Lembo and Cavalli, 2010). A 
tetravalent dengue system composed of bovine serum albumin NPs was evaluated in a murine model. 
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The BSA-NPs could absorb the four serotypes of dengue in their inactive form and after 
administration; an induction of anti-DENV IgG antibodies was occurred (Silva et al., 2012). Other 
nanoparticles composed of chitosan/Mycobacterium bovis Bacillus Calmette-Guerin cell wall 
components were able to encapsulate a novel dengue nanovaccine (produced by UV inactivation of 
DENV-2) and showed interesting immunogenic properties in a Swiss albino mouse model by 
generation of humoral and cellular immune responses (Hunsawonga et al., 2015). Polymeric 
nanoparticles of PLA and methacrylic acid copolymers were designed to entrap the peptidomimetic 
compound CGP 57813, a potent inhibitor of an HIV-type protease. Due to its high lipophilicity, it 
showed a poor biodisponibility. While PLA NPs showed an increase of at least two times in the area 
under the plasma concentration-time curve after intravenous injection in mice, no sufficient plasmatic 
levels were detected after oral delivery, and only the methacrylic acid copolymer NPs provided 
reasonable values (Leroux, et al., 1995). However, in other studies PLA NPs demonstrated to be 
feasible drug delivery carriers to enhance the tissue uptake and the targeting of other macromolecules 
with anti-HIV-1 activity (Ham et al., 2009). Also, PLGA NPs have shown interesting applications as 
vaccine-delivery vehicles for the treatment of virus (Demento et al., 2010). 
Polyhexylcyanoacrylate nanoparticles were loaded with saquinavir (another HIV protease inhibitor) or 
zalcitabine (a nucleoside analog) and tested at in vitro conditions in primary human 
monocytes/macrophages. A dose-dependent reduction of HIV type 1 antigen production was observed 
for both types of NPS (Bender et al., 1996). Hexylcyanoacrylate nanoparticles were developed as a 
colloidal azidothymidine (AZT) carrier for specific targeting of the antiviral drug to 
reticuloendothelial cells by oral delivery in HIV patients (Löbenberg et al., 1997). By modifying this 
kind of NP by coating with polysorbate 80, it was possible to change the body distribution of AZT 
after intravenous injection of rats, with a higher concentration of the drug at brain levels. Although the 
drug was attached to the NPs, its efficacy was not reduced (Löbenberg et al., 1998). AZT was also 
encapsulated in polybutylcyanoacrylate (PBCA) and methylmethacrylate–sulfopropylmethacrylate 
(MMA–SPM) nanoparticles, and the study of their permeability across the blood–brain barrier 
elucidated an enhancement in their permeability with a reduction in NP size (Kuo et al., 2006). 
Furthermore, AZT loaded poly-(isohexylcyanoacrylate) nanospheres displayed promising features to 
target the antiviral to the epithelium of intestine and gut-associated lymphoid tissues, which are the 
main reservoirs of HIV in the GI tract (Dembri et al., 2001). The preparation of pH sensitive NPs was 
an interesting alternative to improve the bioavailability of a poorly water-soluble HIV-1 protease 
inhibitor. In this sense, NPs made of the poly(methacrylic acid-co-ethylacrylate) copolymer 
Eudragit®L100-55 were orally delivered to Beagle dogs and led to an increase in the plasmatic 
concentrations due to a selective release of the antiviral close to its absorption site (De Jaeghere et al., 
2000). Shah et al. (2006) demonstrated that poly(ethylene oxide)-modified poly(epsilon-caprolactone) 
(PEO-PCL) NPs were a feasible vehicle for the intracellular delivery of saquinavir. The PEO-PCL 
NPs exhibited spherical shape and uniform size distribution around 200 nm. Their uptake by THP-1 
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human monocyte/macrophage (Mo/Mac) cell line indicated a significantly higher incorporation of the 
drug in comparison with aqueous solution.  
It is important to mention that the surface of the described NPs can be tailored in order to modify the 
biodistribution of the antivirals,  for targeting specific organs and tissues or, with more precision,  
delivering the drug at a particular kind of cell by attachment of ligands that recognize the receptor 
from cell surface (Gunaseelan et al., 2010). 
Although few reports are currently found in the literature, the first products are appearing on the 
market and a new tendency is indicating that nanocrystals could be a possible delivery system to 
improve the bioavailability of antiviral drugs (Shegokar and Müller, 2010). For example, pure 
quercetin, a flavonoid with anti-dengue virus activity, showed a limited in vivo efficacy because of its 
low solubility and reduced absorption at intestine level. However, synthesis of four types of cocrystals 
led to an improvement in physicochemical and pharmacokinetic characteristics in comparison with 
quercetin alone (Smith et al., 2011). Other reports described the use of cellulose nanocrystals (CNCs) 
as viral inhibitors. A first approach was carried out with unmodified CNCs derived from tunicates in a 
single model bacteriophage, and a decrease in phage infection of host E. coli was observed (Serizawa 
et al., 2013). In a next step, the modification of CNCs by surface attachment of multivalent displays of 
tyrosine sulfate mimetic ligands resulted in inhibition of the alphavirus infectivity in Vero cells. 
Considering these results and the chemical structure of other known polyanionic inhibitors, the 
potential use of CNCs for inhibition of other viruses, such as (HIV) and herpes simplex viruses, should 
be explored (Zoppe et al., 2014). A recent work also reported the production of nanocrystals of a 
reverse transciptase inhibitor from HIV-1 virus (CSIC) by a three-phase NP engineering technology 
for intravaginal delivery (Gong et al., 2014). 
Finally, in the last decade new research papers have shown the potentiality of metal NPs for the 
treatment of virus infections (Durán et al., 2016a). The interaction of silver and gold NPs with proteins 
is under exploration, and the mechanism of antiviral activity is not totally established (Bhattacharya et 
al., 2008; Durán et al., 2016b). However, it was observed that gold NPs conjugated to fragments of the 
HIV inhibitor TAK-779 (named SDC-1721) showed an excellent antiviral effect, while only free 
SDC-1721 had no activity. This means that gold NPs are able to convert inactive molecules into potent 
antivirals (Bowman et al., 2008). On the other hand, silver NPs have also shown interesting properties 
by interacting with HIV virus and therefore preventing the binding to host cells, as long as they are in 
the range of 1-10 nm in size (Elechiguerra et al., 2005). The green synthesis of metal NPs has been 
proposed as an alternative to chemical methods, particularly through the use of fungi, since the benign 
environment and renewable source of fungi act as a reducing agent for the synthesis of metal NPs  
(Durán et al., 2010b, 2015). These kinds of NPs have exhibited a tested efficacy against mosquito 
larvae (Salunkhe et al., 2011; Soni and Prakash, 2012abcd; 2013). In addition, leaf extracts from plants 
have been utilized for silver NP production and become an eco-friendly alternative for adulticidal 
activity against filariasis, malaria, and dengue vector mosquitoes (Suganya et al., 2013; Veerakumar et 
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al., 2014). Sujitha et al. (2015), Murugan et al. (2015b, 2016c) used biogenic silver NPs against DEN2 
and its mosquito vector Aedes aegypti.  
 
FINAL REMARKS 
Since there are very few recently published reviews focusing on leishmaniasis, malaria, 
schistosomiasis, trypanosomiasis, tuberculosis, onchocerciasis, leprosy, filiarasis, and degue virus, the 
present review pointed out the most relevant advances in these areas. Despite the short time of 
nanotechnology in the public scenario, it has brought novel tools for therapeutic purposes of several 
diseases, and it is going to have a high impact on the treatment of ND. Nanocarrier development has 
demonstrated promising results in the therapy of many of these diseases with less toxicity, enhanced 
efficacy and improved bioavailability of drugs, as well as prolonged drug release with a limited 
number of doses. Particularly, the development of green technologies for the synthesis of nanodevices 
and the use of natural compounds with biocide activities are going to be a future trend for the 
development of novel and more efficient ND therapeutics by reducing patient complaints and 
improving their quality of life. Finally, this review deals with the current status of nanobiotechnology 
in the treatment of neglected diseases and describes many possible tools to explore new procedures in 
the treatment of a wide range of diseases, mainly neglected ones. One important aspect is the concern 
not only about neglected diseases, but also about the elimination of disease vectors. Therefore, it is 
clear that it is possible to extensively use nanotechnology to manage these diseases that are ignored by 
the goverments and the pharma and chemical industries. 
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Figures 
 
Fig. 1. Chronological cartoon of relevant TB and anti-TB therapies. Updated from Lalloo and 
Ambaram, 2010. 
 
 
Fig. 2. Nanostructures used in nanobiotechnology. 
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Fig. 3. Solid Lipid Nanoparticles (SLN) for treatment of infections. A) TEM image of SLN prepared 
by ultra-sonication method (unpublished result). B) Controlled release profile of levofloxacin 
form SLN and NLC. Reproduced from Islan et al. (2016) with permission. 
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Fig. 4. Nanoparticles designed to specifically bind the malaria parasite using ligands for attachment to 
host cells, and thus blocking the invasion. A) Parasite (blue, DAPI) with NPs (red, hydrophilic 
sulforhodamine B dye) bounded on surface and recorded with a super-resolution 3D structured 
illumination microscopy (scale bar 1 micron). B) TEM image of an ultrathin portion of 
untreated parasite. C) TEM images of parasite treated with NPs that specifically bind on the 
surface (scale bar 500 nm). It could be observed the nucleus (nu), the rhoptries (rh) and the 
dense granules (dg) of the merozoites (Najer et al., 2014). Adapted from Najer et al., (2014) 
with permission. 
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Fig. 5. In vivo efficacy studies of β-lapachone (β-LP) loaded chitosan NPs in Leishmaniasis treatment. 
A) Lesion size in L. major infected BALB/c mice after 21 days of treatment with topical β-LP 
loaded NP (20 mg/kg day) is reduced in comparison with untreated control (***P< 0.001). B) 
Photograph showing a control mouse (left) and a mouse treated with β-LP NP (right). C-F) 
Parasite burden comparison after 21 days treatment in skin (C), liver (D), spleen (E) and lymph 
node (F). No reduction in the parasite burdens are observed compared to the control group. 
Reproduced from Moreno et al. (2015) with permission. 
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Fig. 6. Polydispersed silver nanoparticles using Malva sylvestris extracts. A) Scanning electron 
microscopy (SEM) images of nanoparticles at ×25,000. B) Larvicidal activity of aqueous leaf 
extract (a) and silver nanoparticles (b) against the mosquito vectors Anopheles stephensi, 
Aedes aegypti, and Culex Quinquefasciatus. Lethal concentration: LC50 (dark grey) and LC90 
(soft grey). Reproduced from Govindarajan et al. (2016c) with permission.  
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Tables 
 
Table 1.  
Recent developments on novel antituberculosis drugs (modified from Lallo and Ambaram, 2010). 
 
Drug Targets Clinical phase 
Class Name 
Diarylquinoline Bedaquiline 
TMC207 
ATP synthase IIb 
Ethylenediamine SQ109 Cell wall (mycolic acid) I 
Fluoroquinolones Gatifloxacin 
Levofloxacin 
Moxifloxacin 
DNA gyrase III 
Iminophenazine Clofazimine DNA synthesis and enhance 
phospholipase A2 
In the market 
Nitroimidazole Delanamid 
PA-824 
TBA354 
Cell wall (blocking mycolic 
acid synthesis and release 
intracellular nitric oxide 
IIa 
Rifamycins Rifabutin 
Rifampicin 
Rifapentine 
RNA polymerase IIb 
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Table 2 
Marketed drugs for the treatment of malaria. 
 
 
 
  
Drug Targets 
Class Name 
Aminoalcohols Halofantrine 
Lumefantrine 
Complex formation with hemin. 
Inhibition of nucleic acid and protein 
synthesis 
4-Aminoquinolines  Chloroquine 
Amodiaquine 
inhibition of hematin formation (heme 
polymerase) 
8-Aminoquinolines Primaquine 
Tafenoquine 
Radical formation with NADPH 
Biguanides Proguanil 
(Chloroguanide) 
Antifolate 
Alcoholquinolines  Mefloquine 
Quinine  
Quinidine 
Polymerization inhibition of haeme to 
hemozin 
Diaminopyrimidines Pyrimethamine Inhibition of hematin formation (heme 
polymerase) 
Naphthoquinone Atovaquone Anti-mitochorndial activity (electron 
transport) 
Naphthyridine Pyronaridine Inhibits -hematin formation 
Sesquiterpine 
lactones 
Artermisinin 
Arteether 
Artemether 
Artesunate 
Interference with parasite transport 
proteins, disruption of parasite 
mitochondrial function 
Sulfonamides - 
sulfones 
Dapsone 
Sulfadoxine 
Sulfamethopyrazine 
Inhibition of dihydropteroate synthase 
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Table 3  
Lipidic based nanocarriers for treatment of neglected diseases. 
 
Device  Encapsulated drug Properties Illness References 
Liposomes Amphotericin B - Displayed a significant 
reduction in treatment 
toxicity. 
- In vitro trypanocidal 
activity. 
Leishmaniasis; 
Trypasomiasis 
Balasegaram 
et al., 2012; 
Papagiannaro
s et al., 2005;  
Cencig et al., 
2011. 
 Anthelmintic, tartar emetic, 
praziquantel 
- Antiparasitic activities after 
injected subcutaneously.  
- Decrease the amounts of 
eggs and worms of 
schistosomes by oral 
delivery. 
Schistosomiasis Melo et al., 
2003; 
Mourao et 
al., 2005; 
Freeza et al., 
2013. 
 Artemether, arteether, 
artesunate, chloroquine, 
artemether/lumefantrine, 
sulphadoxine/pyrimethamine, 
chlorproguanil/dapsone, 
mefloquine, 
atovaquone/proguanil, 
primaquine, artemisinin 
- Protect drugs from 
degradation. 
- Controlled release and 
fewer adverse effects. 
- Increase the blood-
circulation time. 
Malaria Date et al., 
2007; 
Owais et al., 
1995; 
Isacchi et al., 
2011. 
 Clofazimine - Enhanced antibacterial 
activity against M. leprae. 
Leprosy Patel et al., 
1999; Patel 
and 
Misra, 1999. 
 Diethylcarbamazine citrate, 
tetracycline 
- Effective in the elimination 
of filarial parasites from 
systemic circulation. 
- Increased the time of drug 
release. 
Filiarasis Owais et al., 
2003; Bajpai 
et al., 2005. 
 Etanidazole - Decrease the parasitemia 
levels of T. cruzi in 
infected mice after 
endovenous administration.  
Trypasomiasis Salomon, 
2011. 
 Iminosugars - Enhance the antiviral 
activity and drug 
circulation in blood.  
Dengue Miller et al., 
2012. 
 Rifampicin, pyrazinamide, 
rifabutin 
- High concentration of the 
drug in the target organ 
(e.g., lungs). 
- Higher antimicrobial 
activity. 
Tuberculosis Kaur IP and 
Singh 2014; 
Kaur M. et 
al, 2014. 
 Tearylamine, antigens against 
T. Gondii, triclosan 
- Preventive and curative 
effects.  
- Longer release phase, 
prolonging the drug action 
in peritoneal fluid and in 
the liver. 
Toxoplasmosis Tachibana et 
al., 1990; 
Elsaid et al., 
1999, 2001; 
El-Zawawy 
et al., 2015. 
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Lipidic 
NPs (SLN, 
NLC and 
LCN) 
Amphotericin B, oryzalin - Increaase 40 times the 
AmB bioavailability 
compared with free drug. 
- Decrease its toxicity. 
Leishmaniasis Jung et al., 
2009; Lopes 
et al., 2014. 
 Artemether in NLCs. - Reduce the parasite burden 
instantly.  
Malaria Parashar et 
al., 2014. 
 Diethylcarbamazine citrate - Elimination of microfilariae 
from the lymphatics. 
Filiarasis Kartick, 
2014. 
 5-Hydroxy-3-methyl-5-
phenyl-pyrazoline-1-(S-
benzyl 
dithiocarbazate) in SLNs. 
- Show in vitro and in vivo 
trypanocidal activity.  
Trypanosomiasi
s 
Carneiro et 
al., 2014. 
 Praziquantel in SLNs - Increase the oral 
praziquantel bioavailability 
in rats. 
- Decrease toxicity in HepG2 
cells when compared to 
free prazinquantel. 
Schistosomiasis Mishra et al. 
2014; Yang 
et al., 2009; 
Souza et al., 
2014. 
 Pyrimethamine in LNC  - Increase the survival rate of 
infected animals. 
Toxoplasmosis Pissinate et 
al., 2014. 
 Rifampicin, isoniazid, 
pyrazinamide 
- Exhibit a better therapeutic 
efficacy in Guinea pigs.  
Tuberculosis Kaur IP and 
Singh, 2014; 
Kaur M. et 
al, 2014. 
Abbreviations: SLN, solid lipid nanoparticles; NLC, nanostructured lipid carriers; LCN, lipid-core nanocapsules. 
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Table 4  
Examples of nanocarriers based on polymers and natural macromolecules developed for neglected 
disease therapies. 
 
Polymer/device Encapsulated drug Properties Illness References 
Chitosan NPs Amphotericin B,  
β-lapachone 
- Effective in reducing the 
infection in animal 
models infected with L. 
amazonensis. 
- Decrease toxicity of free 
drug. 
- Important drug 
accumulation in the 
dermis and permeation 
through the skin. 
Leishmaniasis Ribeiro et al., 
2015.; Moreno 
et al., 2015. 
 Chloroquine - Effective against P. 
berghei infection in Swiss 
mice model. 
Malaria Tripathy et al., 
2012, 2013. 
 Isoniazid, rifampicin - Efficacy against 
mycobacterium. 
- Sustain deliver of the 
drugs. 
Tuberculosis Garg et al., 
2016 
 Mycobacterium bovis 
Bacillus Calmette-
Guerin cell wall 
components. 
- Dengue nanovaccine. Dengue Hunsawong et 
al., 2015. 
 Pentamidine  
(NPs coated with 
nanobodies) 
- Diminish the minimal 
effective therapeutic dose 
(in vivo). 
- Increasing its efficacy. 
- Diminish toxicity. 
- Overcome drug resistance 
mechanisms. 
Trypasomiasis Unciti-Broceta 
et al., 2015. 
Gelatin NPs Amphotericin B - High accumulation of 
AmB in liver and spleen.  
- Enhance anti-leishmanial 
activity.  
Leishmaniasis Khatik et al., 
2014. 
PLGA NPs β-Aescin, artemisinin 
 
- Reduction in cytotoxicity. 
- Maintenance of anti-
leishmanial efficacy. 
Leishmaniasis Van de Ven, 
2011; Want et 
al., 2015. 
 Ivermectin - Enhanced microfilaricidal 
effectiveness. 
- Slightly better 
macrofilaricidal 
effectiveness. 
Filiarasis Ali et al., 2014. 
 Prazinquantel - Localized effect on 
intestinal membranes. 
- Prolonged period of time. 
- Increase water solubility 
and chemical stability. 
Schistosomiasis Mainardes and 
Evangelista, 
2005; Fonseca 
et., 2013; 
Mainardes et 
al., 2006. 
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 Rifampicin, 
isoniazid, 
pyrazinamide 
- Strong therapeutic 
efficacy. 
- High encapsulation 
efficiency. 
- Prolonged plasma drug 
levels. 
- Greater dispersibility. 
Tuberculosis Kaur and 
Singh, 2014; 
Kaur M. et al., 
2014. 
 Bis-Triazole DO870  - Produce a significant cure 
of mice infected with T. 
cruzi. 
Trypanosomiasis Urbina et al., 
2001; Molina 
et al., 2001. 
Other 
biodegradable 
NPs 
Allopurinol, 
grandisin, violacein, 
bis-triazole DO870, 
and megazol 
- Show great in vitro 
trypanocidal activity.  
Trypanosomiasis Gonzalez-
Martin et al., 
2000; Duran et 
al., 2001; 
Molina et al., 
2001; 
Stecanella et 
al., 2013; Lima 
and 
Albuquerque, 
2012. 
Abbreviation: PLGA, Poly Lactic-co-Glycolic Acid. 
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Table 5  
Nanoemulsions, nanosuspensions and nanocrystals in treatment of Neglected Diseases. 
 
Encapsulated drug Properties Illness  References 
Semisynthetic derivatives of 
artemisinin, artemether and 
arteether 
- Enhance treatment for 
uncomplicated P. falciparum 
malaria. 
- Improve drug solubility and its 
bioavailability. 
Malaria Dwivedi et al., 
2015. 
2-(butylamino)-1-phenyl-1- 
ethanethiosulfuric acid (BphEA) 
- Higher schistosomicidal activity 
compared to free BphEA, 
Schistosomiasis Araujo et al., 
2007. 
Essential oils of andiroba (Carapa 
guaianensis) and aroeira (Schinus 
molle) 
- High in vitro efficiency against 
T. evansi.  
Trypanosomiasis Baldissera et al., 
2013. 
Dapsone (4,4'-
diaminodiphenylsulfone) 
- Enhanced bacteriostatic action 
against M. leprae. 
- Improve the clinical use by 
increasing the bioavailability. 
Leprosy Santos et al., 
2012; Borges et 
al., 2013, 
Monteiro 
et al., 2012. 
Ramipril - Improve the bioavailability. Tuberculosis Kaur and Singh, 
2014; Kaur et al., 
2014. 
Diethylcarbamazine citrate - Exhibited great potential as a 
lymphotropic vehicle system. 
Filiarasis Karajgi 
and Vyas, 1994. 
Atovaquone capped with 
poloxamer 188 (P188) and sodium 
dodecyl sulfate (SDS) 
- Increase the oral bioavailability 
and decrease the inflammatory 
signs in brain of animals. 
- Decrease the infection capacity 
of parasite. 
Toxoplasmosis Shubar et al., 
2011; Scholer et 
al., 2001. 
Essential oils (from Rosmarinus 
officinalis  
- kill the mosquito larva of Aedes 
aegypti.  
Dengue Duarte et al., 
2015. 
Hemozoin (NC) - Kill the malaria parasite in 
theranostic applications.  
Malaria Hleb and 
Lapotko, 2014. 
Clofazimine (NC) - Reduce the bacterial load in 
lungs. 
Tuberculosis Kaur and Singh 
2014; Kaur et al, 
2014. 
Quercetin (NC) - Enhance the anti-dengue virus 
activity of the drug by increasing 
bioavailability  
Dengue Smith et al., 
2011. 
Silver (NC) - Kill the mosquito larvae Zika Govindarajan et 
al., 2016c. 
Abbreviation: NC, nanocrystals. 
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Table 6 
Metal nanoparticles for the treatment of Neglected diseases. 
 
Carrier Properties Illness  References 
Biologically 
generated silver 
NPs 
- Show in vitro antiviral activity against 
DEN-2 infecting vero cells. 
- Effective against the dengue vector A. 
aegypti. 
Dengue Sujitha et al., 2015; 
Murugan et al., 
2015 and 2016. 
 - Exhibit good activity against larvae of C. 
quinquefasciatus. 
- Larvicidal activity against the mosquito 
vector of lymphatic filariasis (Culex sp.). 
Filariasis Rajakumar and 
Rahumam, 2011; 
Dhanasekaran and 
Thangaraj, 2013. 
 - Are administered by subcutaneous 
intralesional route in experiments against 
Leishmania amazonensis promastigotes.  
- Demonstrate to be 4 times more effective 
than chemically generated AgNPs.  
- Showed the same effectiveness than 300-
fold higher doses of amphotericin B. 
- Are more effective than 3-fold higher doses 
of Chem-AgNP.  
Leishmaniasis Rossi-Bergmann et 
al., 2012. 
 - Molluscicidal activity with low toxicity to 
other aquatic organisms. 
Schistosomiasis Yang et al., 2011; 
Guang et al., 2013. 
 - Toxic effects against Anopheles stephensi, 
Aedes aegypti, and Culex quinquefasciatus 
larvae. 
- Eco-friendly.  
Zika Govindarajan et al., 
2016a,b. 
Chemically 
synthesized 
silver NPs 
- Reduce the parasite counts with Ag levels in 
the accepted range of toxicity. 
Toxoplasmosis Gaafar et al., 2014. 
Gold and silver 
NPs 
- Bound tightly to the arginine substrate that 
selectively inhibit an arginine kinase present 
in the microorganism but absent in humans.  
- Become candidates for trypanocidal drug 
studies.  
Trypasomiasis Miranda et al., 
2006; Adeyemi and 
Whiteley, 2014. 
Abbreviation: NPs, nanoparticles. 
 
 
 
